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General inTroduCTion
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Special situations in MS
Multiple sclerosis (MS) is a chronic, incurable disease. Currently, treatments offered 
to patients with MS do not substantially prevent progressive disability. The Holy Grail in 
MS research is to develop a definitive cure for MS or at least a method for halting disease 
progression. Greater knowledge about the etiology and pathogenesis is required to be able 
to move forward towards a better treatment.
Central to this thesis is the concept that through study of natural disease course and 
natural modifiers, crucial lessons can be learned about etiology, pathogenesis, prognosis 
and perhaps ultimately new treatment options in MS. This thesis will focus on two special 
and different situations in MS: pregnancy and MS, and childhood onset of MS. 
Pregnancy strongly influences disease course in MS. The number of relapses in MS 
is decreased during pregnancy. However, during the first three months after delivery 
the number of relapses increases. Alterations in the immune system during pregnancy, 
essential for a successful pregnancy, likely cause this disease amelioration. Studying clinical 
features and immune functions during and after pregnancy in MS can provide insight into 
the pathogenesis of MS in general. It can also prove to be of clinical benefit to women with 
MS that are pregnant or have a childwish, in supplying both patients and doctors with more 
detailed information about disease course around pregnancy. Furthermore it may reveal 
possible biomarkers for predicting postpartum relapse.
In a small minority of patients clinical debut of MS occurs in childhood. Diagnosis of MS 
in children can be difficult, because of the many diseases that can mimic MS in childhood. 
More information about natural disease course could therefore help to improve diagnosis 
and management of MS in these children. Furthermore, MS in children allows better study 
of potential risk factors involved in pathogenesis, that are present early in life, than is 
possible in patients with an adult onset.
The subsequent parts of this introduction will discuss respectively in more detail: the 
general aspects of MS, pregnancy in MS, and childhood onset of MS. This chapter will 
conclude with the scope and outline of this thesis.
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i. General aSPeCTS of MulTiPle SCleroSiS
MS is a chronic inflammatory disease affecting the central nervous system (CNS).1 It is the 
most common chronic neurological disease in young adults. MS affects all regions of the 
CNS, including the optic nerve. Patients can have a broad spectrum of signs and symptoms, 
including problems with ambulation, visual and sensory disturbances, fatigue and cognitive 
disorders. 
Epidemiology
MS has a life time prevalence of 1 per 1000 individuals in the western world.1 Women are 
more often affected than men with a male to female ratio of 1:3.2-3 This gender difference 
in incidence becomes apparent after puberty. Before puberty the male to female ratio is 
1:1.4 Age of onset follows a unimodal distribution with a peak between the ages of 20 to 40 
years.5 For women the onset of MS thereby falls in the childbearing years. MS can also have 
its onset in childhood. In up to 5.0% of the total MS population, onset of MS is before the age 
of 16 years and in less than 0.6% onset is before the age of ten years.3,6-9 
Disease course
Most patients (80-90%) experience a relapsing remitting (RR) disease course (Figure 1). A 
minority (10-20%) of the adult patients exhibit a primary progressive (PP) disease course. 
PP-MS in children is very rare.1,9-11 RR-MS is characterized by exacerbations followed by a 
variable extent of improvement. A majority (65%) of these patients with RR-MS eventually 
develop a secondary progressive disease course, in which the disease progresses slowly and 
exacerbations tend to be less frequent.1 Patients with a childhood onset take years longer to 
develop irreversible disabilities, but do so at a younger age than adult onset MS (Figure 2).9-11 
Diagnosis of MS
A golden standard for the diagnosis of MS is lacking. Instead, the diagnosis of MS relies on 
a combination of clinical and/or paraclinical parameters. Widely accepted criteria for the 
diagnosis are the revised McDonald criteria.12 The McDonald criteria allow for an early and 
reliable diagnosis. Essential for the diagnosis MS is dissemination in time and in space. When 
clinical features fail to provide evidence of dissemination in time and space, paraclinical 
features can be used to fulfil diagnostic criteria, such as magnetic resonance imaging (MRI), 
visual evoked potentials or presence of intrathecal (oligoclonal) antibody production. 
When clinical criteria for dissemination in space or in time cannot be fulfilled, the Barkhof 
MRI criteria for dissemination in space or the Barkhof MRI criteria for dissemination in time 
can be used (Table 1). The specific criteria for the diagnosis PP-MS are depicted in Table 2.12
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figure 1. disease course in multiple sclerosis (MS)
The majority of MS patients (80-90%) start with a relapsing-remitting (RR) disease course, during which 
they suffer alternating periods of clinical symptoms followed by (partial) recovery. Around 60-70% of these 
RR patients eventually develop a secondary progressive disease course, characterized by a slow and gradual 
progression of clinical symptoms. A minority (10-20%) of the adult patients exhibit a primary progressive 
(PP), characterized by a slow and gradual progression of clinical symptoms without an RR phase.
diagnosis MS
severe disability
age (years)180
adult onset
childhood onset
figure 2. Clinical course differs in childhood and adult onset in multiple sclerosis (MS)
Time from diagnosis to severe disability is longer in patients with childhood onset MS (dotted line) than 
in adult onset MS (fixed line). Nevertheless, patients with childhood onset MS reach severe disability at a 
younger age.
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Table 1. barkhof Mri criteria for diagnosing MS12
barkhof criteria for dissemination in place
(at least 3 out of 4)
barkhof criteria for dissemination in time
(at least 1 out of 2)
≥1 gadolinium-enhancing lesion or ≥9 T2 lesions * Gadolinium enhancement at ≥3 months after 
onset of the initial clinical event, if not at the 
site corresponding to the initial event.
≥1 infratentorial lesion ** Detection of a new T2 lesion if it appears at 
any time compared with a reference scan 
done at least 30 days after the onset of the 
initial clinical event.
≥1 juxtacortical lesion
≥1periventricular lesion
* An enhancing spinal cord lesion is considered to be equivalent to an enhancing brain lesion, and individual 
spinal cord lesions can contribute together with individual brain lesions to reach the required number of 
T2 lesions. 
** A spinal cord lesion can be considered equivalent to a brain infratentorial lesion.
MS: Multiple sclerosis
Table 2. Mcdonald criteria for the diagnosis primary progressive multiple sclerosis12
1 One year of disease progression (prospectively or retrospectively determined)
2 Plus two out of these three criteria
a Positive brain MRI (≥9 T2 lesions or ≥4 T2 lesions with positive VEP)
b Positive myelum MRI (≥2 focal T2 lesions)
c
Positive CSF (increased IgG-index or isoelectric focussing evidence of oligoclonal IgG bands 
(or both)
VEP: visual evoked potential, CSF: cerebrospinal fluid
Pathogenesis of MS: focus on immunology
The exact cause of MS is unknown. MS is presumed to be the effect of an unfortunate 
interplay between environmental exposure and genetic susceptibility.1 
MS is considered to be an inflammatory disease of the central nervous system (CNS).1,13 
Active lesions in MS are characterized by disruption of the blood brain barrier (BBB), local 
edema and demyelination.14 Macrophages containing myelin associated proteins and T cells 
and are found surrounding damaged myelin sheaths.14 Perivascular radial demyelination 
with sharp borders and axonal injury is observed .14-15 In the chronic phase of the lesion no 
active demyelination is observed, but instead a process of gliosis and reduced axonal density 
is found.14
Natural killer (NK) cells and antigen presenting cells (APC), like monocytes, macrophages, 
and dendritic cells of the innate arm of the immune system present autoantigens to T cells 
of the adaptive arm of the immune system (Figure 3). Auto reactive lymphocytes migrate 
through the disrupted BBB. Disease activity is mediated by interferon γ (IFN-γ) secreting 
CD4+ Thelper 1 (Th1) cells. Recently, an important pro-inflammatory T cell subset of 
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interleukin (IL)-17 producing T helper cells (Th17) has been implicated in MS disease activity, 
controlled by IL-1, IL-6, IL-18, IL-23 and possibly IL-21.13,116-17 This Th17 subset is involved in 
BBB disruption and brain inflammation.18 The immunosuppressive regulatory T cells (Treg) 
form another important T cell subset in MS. Treg play an important role in the maintenance 
of self-tolerance in autoimmune animal models and are controlled by transforming growth 
factor β (TGF-β).13,19 Defects in regulatory T cell function have been described in MS.20-22 
central nervous system
Th17
Th1
Th2
Treg
APC Th0
IL-1, IL-6, IL18
IL-4, IL-10
IL-10, TGF-β
TNF-α, IFN-γ
IL-21, IL-23
IL-17
IL-4
IL-12
regulatory effects
pro-inflammatory
anti-inflammatory
figure 3. T cell differentiation in multiple sclerosis (MS)
Antigen presenting cells (APC) present autoantigens to naïve CD4+ T cells (Th0). The most relevant cytokines 
are depicted for differentiation towards T helper (Th)1, Th2, Th17 cells and regulatory T cells (Treg). Disease 
activity in multiple sclerosis (MS) is probably driven by pro-inflammatory Th1 and Th17 cells. Th2 cells and 
Treg likely protect against MS.
ii. PreGnanCy aS a naTural Modifier of MS
Pregnancy is the only known natural modifier of disease course in MS.1,23 During the last 
trimester a striking reduction of 70% in relapse frequency is reported, whereas interferon 
beta therapy results only in a 30-35% reduction of the relapse rate.1 Understanding the 
underlying biological mechanisms of this powerful natural modifier of MS will give better 
understanding of pathogenesis and possibly treatment of MS. 
A. Clinical features of MS and pregnancy
Influence of pregnancy on MS disease course
MS presentation in women happens often in the childbearing years.1 Onset risk of MS is 
reduced during pregnancy.24 Pregnancy has an ameliorating effect on clinical disease activity, 
which is schematically shown in Figure 4. During the third trimester, at a group level, the 
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annualized relapse rate decreases with 70%, compared to the year preceding pregnancy. 
During this third trimester only one in every twenty women will have a relapse. However, 
in the first three months after delivery disease activity is known to rebound, resulting in a 
relapse in one in every three women with MS.23,25-27 A year after delivery the relapse rate is 
normalized and comparable with the year preceding pregnancy.23,25 
Illustrative of decreased disease activity is the reduced number of lesions on MRI during 
pregnancy as was reported by a case report showing MRI data of two pregnant patients that 
were included in a sequential MRI study.28 After delivery an increase in the number of new 
or enlarging MRI lesions was observed.29 
The numbers of relapses in the year preceding pregnancy and during pregnancy in 
addition to the duration of disease were unfavourable predictors of postpartum relapse, 
although with poor sensitivity and specificity.25 A recent study showed that exclusive 
breastfeeding was protective against postpartum relapse.30 Yet, many other studies failed 
to find an association between breastfeeding and postpartum relapse.23,25-26,31-32 We can 
conclude that good clinical predictors of postpartum relapse are lacking. Instead of clinical 
predictors, biomarkers could be an alternative for predicting postpartum relapse. Currently, 
no biomarkers have been identified that are able to reliably predict postpartum relapse.
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figure 4. relapse rate before, during and after pregnancy
During pregnancy, an evident drop in relapse rate is observed during the last three months of pregnancy, 
whereas in the first three months after delivery the relapse rate rebounds and overshoots. One year after 
delivery, the relapse rate is comparable with the year preceding pregnancy.
Influence of MS on pregnancy and pregnancy outcome
No major adverse effects in birth outcome have been reported in mothers with MS.27,33-34 
Neonates being born to mothers with MS were more frequently small for their gestational 
age (13%), in comparison to neonates being born to healthy mothers (11%).33 This was not 
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confirmed in another cohort.27 Women with MS have a slightly higher percentage (26-32%) 
of medically assisted deliveries (forceps or vacuum-assisted delivery or caesarean section), 
compared to healthy mothers (20-23%).27,33 These data may be partially biased because the 
MS mothers in these studies were three years (mean) older than the healthy mothers.
Pregnancy in systemic lupus erythematosus and rheumatoid arthritis.
In other autoimmune disorders such as systemic lupus erythematosus (SLE) and rheumatoid 
arthritis (RA), disease course is also altered during pregnancy. SLE is a systemic autoimmune 
disease affecting mostly women in their childbearing years. Multiple studies on disease 
activity have been published and were reviewed recently.35-36 Large differences between 
studies on disease activity during pregnancy were observed. These conflicting results 
could mostly be explained by different disease definitions and definitions of a SLE flare. 
An increase of SLE activity during pregnancy was found in most studies. In RA, a majority 
of patients (65-90%) experience an improvement during pregnancy.35-36 After delivery, an 
increase of disease activity was observed in approximately 80-90% of RA patients.36 
B. Pregnancy-induced tolerance: a link to MS amelioration during pregnancy?
Because the fetus expresses paternal antigens, it is considered to be semi-allogenic. 
Rejection of these paternal antigens, expressed by trophoblast cells in early implantation 
and pregnancy, is inhibited.37-38 A well known proposition is that the adaptive arm of the 
immune system is skewed during pregnancy from a pro-inflammatory phenotype towards 
an anti-inflammatory phenotype.37-40 Compensating for the decreased adaptive pro-
inflammatory immune functions, activity of innate immune functions increases, allowing 
both a successful pregnancy and defence against infections during pregnancy.38,41-43 
 As pregnancy induces altered immunological activity and MS and other autoimmune 
diseases display an altered disease course during pregnancy, it is logical to study changes in 
the innate and adaptive arms of immune system during pregnancy in MS.
C. Biology of normal pregnancy
In this part I will respectively discuss the immunological changes in the uterus, the changes 
of the adaptive arm of the immune system and finally the changes in the innate arm of the 
immune system.
Normal pregnancy: The uterus as an immune privileged site
The semi-allogenic fetus is allowed to grow inside the uterus. This tolerance against 
paternal antigens is not systemic, but limited to the uterus. Therefore, this pregnancy-
induced tolerance is not a case of central immunological tolerance.44 In human pregnancy, 
fetal trophoblast cells invade the decidua and replace the endothelium of the uterine spiral 
arteries, thus ensuring adequate blood supply. The interface between the fetal placenta 
and the maternal decidua is one of the supposed sites of this regulation of tolerance and is 
shown in Figure 5. This implantation side is infiltrated with maternal leucocytes. Most of 
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these cells are NK cells, next to monocytes and T cells.38 A second interface between the fetal 
semi-allograft and the maternal immune system is the syncytiotrophoblast, that forms the 
villous surface of the haemochorial placenta.45-46 Syncytiotrophoblast cells do not express 
detectable levels of major histocompatiblity complex (MHC) class I and class II molecules. 
Trophoblast cells do not express MHC class II molecules, which can be recognized by CD4+ 
T cells. Also the classical MHC class I molecules human leucocyte antigens (HLA)-A, HLA-B 
and HLA-D are not expressed by trophoblast cells. This lack of classical MHC class molecules 
helps limiting maternal T cell awareness of the semi-allogenic fetus. Trophoblast cells do 
express the MHC class I molecules HLA-C, HLA-E and HLA-G, which interact with the uterine 
NK cells.45,47 HLA-E has a role in inhibition of NK cytotoxicity.48 Interestingly, the killer cell 
immunoglobulin-like receptors (KIRs), produced by NK cells, show an expression pattern 
that is biased towards recognition of HLA-C. HLA-C is the only polymorphic classical MHC I 
molecule expressed by placental trophoblasts that is in direct contact with uterine tissue.46,49 
These KIR receptors also interact with HLA-E and HLA-G.38 
Another mechanism for maternal immune suppression is placental production of 
indoleamine-2,3 dioxygenase (IDO).50 IDO can inhibit proliferation and function of T cells by 
depletion of tryptophan in T cells. Catabolites of trypotophan are also able to inhibit T cell 
proliferation.51
Galectin-1 recently gained much attention. This glycan binding protein is synthesized by 
a wide variety of cells including immune cells. Galectin-1 can modulate T cell homeostasis by 
interfering with T cell activation, promoting T cell apoptosis, T cell migration and regulating 
Th1/Th2 cytokine balance towards Th2 predominance.50,52-53 Galectin-1 has an important 
role at the feto-maternal interface and is secreted by decidual tissue.52
Normal pregnancy: adaptive immunity 
Human CD4+ T helper lymphocytes can be classified into functional subsets on the basis of 
their pattern of cytokine production.54 Type 1 CD4+ T cells (Th1 cells) produce interleukin-2 
(IL-2), tumor necrosis factor alpha (TNF-α) and interferon-gamma (IFN-γ). Th1 cells are the 
main effectors of phagocyte-induced host defence. On the other hand, type 2 CD4+ T cells 
(Th2 cells) produce IL-4, IL-5, IL-13 and IL-10. Th2 cells are mainly responsible for phagocyte-
independent host defence. The Th1/Th2 paradigm has long dominated the discussion 
around pregnancy related tolerance. The ratio between the pro-inflammatory Th1 and anti-
inflammatory Th2 cells is changed towards a more Th2 phenotype during pregnancy.37,55 
In recurrent spontaneous abortions and in pre-eclampsia increased Th1 immunity was 
observed.39,55-56 However, Th2 type immunity was also observed in recurrent abortions.41,57 
Knock out mice for the Th2 type cytokines IL-4, IL-5, IL-9 and IL-13 are able to reproduce, 
demonstrating that Th2 type immunity is not essential for successful pregnancy.58 These 
findings suggest that the Th1/Th2 balance shifting theory as an explanation of pregnancy 
related tolerance is too simple.59 More key players in immunology were identified at the 
feto-maternal interface like monocytes and NK cells, as were two functional subsets of 
T cells: Treg and Th17 cells. Treg have been found to be highly important for a successful 
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figure 5. Mechanisms of pregnancy-induced tolerance in normal pregnancy
At the feto-maternal interface several mechanisms are shown that help to inhibit rejection of paternal 
antigens by T cells. The absence of major histocompatiblity complex (MHC) class II molecules limits T cell 
awareness of paternal antigens. Also classical MHC class I molecules human leucocyte antigen (HLA)-A 
and HLA-B are not expressed at the feto-maternal interface. Instead the HLA-C and the non-classical MHC 
class I molecules HLA-E and HLA-G are expressed. HLA-C, HLA-E and HLA-G interact with CD56bright Natural 
Killer (NK) cells by killer cell immunoglobulin-like receptor (KIR) signalling. Numbers of CD56bright NK cells 
are increased in the decidual tissue. Increased expression of indoleamine-2,3 dioxygenase (IDO) limits T 
cell proliferation by depletion of tryptophan in T cells. Catabolites of trypotophan are also able to inhibit 
T cell proliferation. Galectin-1 can modulate T cell function by interfering with T cell activation, promoting 
T cell apoptosis, T cell migration and regulating Th1/Th2 cytokine balance towards Th2 predominance. 
The number of monocytes is increased and they display increased expression of CD14 and increased 
phagocytosis. Normal pregnancy is characterized by an increase of anti-inflammatory Th2 cells and 
a decrease of pro-inflammatory Th1 cells. Regulatory T cells (Treg) migrate into the decidual tissue and 
their numbers in the decidual tissue are increased. There is some evidence that pro-inflammatory Th17 
cells numbers are increased in the decidual tissue. There is no available data on Th17 migration into the 
decidua from the peripheral maternal blood. Data on alterations in numbers of circulating Treg and Th17 in 
peripheral maternal blood are conflicting.
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pregnancy.60 Several studies have examined the frequency of circulating Treg in peripheral 
blood during pregnancy. Both increases and decreases in frequencies of circulating Treg 
were reported.61-67 These differences in frequencies of circulating T cell frequencies are likely 
based on the different flow cytometry gating strategies used to identify Treg populations 
in peripheral blood. Early in pregnancy, increased numbers of Treg are found in the 
decidua.68-69 These decidual Treg are able to inhibit CD4+ T cell proliferation68 and are decreased 
in recurrent abortions, implying a role in the maintenance of successful pregnancy.67-70 The 
frequencies of Th17 cells during pregnancy have not been studied extensively. One study 
showed no change in the frequency of Th17 cells during pregnancy71 while another study 
found decreased numbers of Th17 cells during normal pregnancy.67 Unexpectedly, numbers 
of these pro-inflammatory Th17 cells are increased in the decidua compared to peripheral 
blood.71
Normal pregnancy: innate immunity
As discussed before, in human pregnancy the fetal implantation side is infiltrated by 
monocytes, granulocytes, NK cells and to a lesser extent with T cells. The majority of immune 
cells are derived from the innate arm of the immune system. During normal pregnancy the 
numbers of circulating monocytes and granuloctyes are increased.43 Not only the numbers 
of these cells are increased, the phagocytic function of these cells and the expression of the 
endotoxin receptor CD14 and CD64, the high affinity receptor for the Fc fragment of IgG, is 
increased.43,72-75 Another important cell type at the feto-maternal interface are NK cells. In 
humans, NK cells are divided into two distinct types of cells based on their expression of 
CD16 and CD56.76 CD16negCD56bright cells are poorly cytotoxic, whereas CD16posCD56dim cells 
are highly cytotoxic but poor at cytokine production.53 During pregnancy the numbers of 
CD56dim cells are decreased and numbers of CD56bright cells are increased, both in blood and 
in the decidua.46,53 CD56bright NK cells are able to regulate T cell function by limiting T cell 
survival.77 Trophoblast cells express HLA-C which is the ligand for KIR expressed by uterine 
NK cells. Complex interactions between activating and inhibiting KIR types and HLA-C 
subtypes codetermine the success of pregnancy.78 
Overall, it is clear that the maternal immune system is altered to allow for a successful 
pregnancy, but the precise mechanisms behind these changes and the possible interactions 
of these mechanisms remain to be elucidated.
D. Biology of pregnancy in MS
Immunological changes during pregnancy in MS. What is known? 
MS is considered to be a T cell driven autoimmune disease. Hence most studies on 
immunological changes during pregnancy in MS focussed on T cell subsets, yielding 
conflicting results on Treg frequency in peripheral blood. One study showed an increase of 
the frequency of circulating Treg in peripheral blood during the first two trimesters followed 
by a decrease in the third trimester.79 Another study showed a decrease in Treg during the 
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last two trimesters.80 A study from Finland showed no differences in Treg frequencies 
during pregnancy.81 This last study also found decreased production of the Th1 cytokine 
IFN-γ by peripheral blood cells during pregnancy.81 This was also found before in another 
small study.82 IFN-γ production increased during pregnancy.79 Surprisingly, a recent study 
showed that MS patients with a postpartum relapse have lower numbers of IFN-γ producing 
CD4pos cells during the third trimester.83 No studies have been done on frequency of the pro-
inflammatory Th17 cells during pregnancy in MS.
As soluble CD95 can block CD95 mediated T cell apoptosis, it has been hypothesized that 
pregnancy may induce an alteration in soluble CD95 levels. No evidence of altered levels of 
soluble CD95 in pregnant MS patients was found.84
Innate immune alterations during pregnancy in MS patients were investigated in a 
single study. This study described an increased number of circulating anti-inflammatory 
CD56bright NK cells.80
Soluble HLA-G is increased in the CSF of MS patients. In MS patients high levels of soluble 
HLA-G in serum and CSF are associated with fewer MRI abnormalities.85-86 After delivery in 
MS patients serum level of soluble HLA-G is decreased. This drop in serum level of soluble 
HLA-G was associated with an increased number of postpartum relapses.87 
It is clear that many questions on the biology of pregnancy in MS remain. Some changes 
that have been reported were unexpected and have not been successfully reproduced in 
other cohorts.
Pregnancy in the animal model of MS: of mice and women
Experimental autoimmune encephalomyelitis (EAE) is the animal model of MS. In EAE 
myelin components are injected into susceptible animals, emulsified in very strong 
adjuvants. This leads to a CD4+ T cell mediated autoimmune disease with similarities to 
MS.13,88 The induced EAE in animals does not equal MS in humans, but important lessons can 
still be learned from this animal model. 
Several studies have examined the effect of pregnancy and/or estrogens on EAE. Mice 
immunized during pregnancy showed a decreased incidence of EAE.89 Mice with pre-existing 
EAE that became pregnant displayed an ameliorated disease course.89 In the brain of these 
mice no decrease in inflammatory cell infiltration was observed, compared to non-pregnant 
mice. In murine EAE, immunisation during pregnancy resulted in a decreased incidence 
and clinical severity.90 TNF-α and IL-7 production were decreased and IL-10 production was 
increased. These data were confirmed by a recent study.91 This study also found the presence 
of microparticles, exosomes derived from the serum of pregnant mice, with an immune 
suppressive function. In EAE mice treated with estrogens disease severity was reduced.92-94 
In these estrogen-treated mice IL-10 production was increased.92
Estriol treatment in MS
A cross-over study attempted to mimic pregnancy in women with MS by giving them 
the pregnancy hormone estriol in a dosage (8 mg/day) comparable with levels of estriol 
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found during pregnancy during two periods of six months.95 Six patients with RR MS and 
six patients with SP MS were entered in the study. Ten patients finished the study protocol 
(two SP MS patients were excluded during the study because of protocol violation). Estriol 
treatment did not result in a significant decrease in relapse rate, likely because of the small 
numbers. The patients with RR-MS showed a decrease in MRI disease activity and a decrease 
in IFN-γ production by peripheral blood mononuclear cells (PBMC). Also an increased 
production of the Th2 cytokines IL-5 and IL-10 by PBMC was observed. This increase of IL-10 
was possibly due to an increased number of CD64+ cells (monocytes/macrophages).96 The 
use of oral contraceptives in the general population is not related with a decreased risk of 
MS.97
Other pregnancy related hormones and MS
During pregnancy cortisol levels increase and they decline after delivery.98 The rise in 
cortisol during pregnancy is driven by placental production of corticotrophin releasing 
hormone (CRH). Hypothalamic production of CRH is decreased during pregnancy and is 
restored around three months after delivery. High levels of cortisol are likely to be beneficial 
to MS, as high dose corticosteroids are used in the treatment of acute relapses in MS.99 No 
studies on cortisol levels during pregnancy in MS have been performed.
The exact role of prolactin in MS is still to be elucidated. Prolactin is implicated in white 
matter regeneration.100 In EAE inhibition of prolactin production by bromocriptin is able 
to reduce severity of EAE.101-102 In MS patients acute relapses are accompanied by a surge 
in prolactin.103-104 A decrease in prolactin accompanied reduced MRI disease activity in 
MS patients treated with monthly pulses of corticosteroids.105 Prolactin levels during MS 
pregnancy have not been studied yet.
iii. When MS STarTS in Childhood
In recent years, the awareness is increased that MS can already start during childhood.106-109 
Establishing a definite diagnosis of MS after a first demyelinating event in children can 
be difficult. Differential diagnosis is more complex than in adults as other diseases may 
mimic MS during childhood. Neurological deficits are sometimes subtle and neurological 
examination of children is more challenging. These factors often lead to both patient and 
doctors delay in the diagnosis of MS.
Studying MS in children can augment understanding of MS in general. Children with 
MS uniquely allow the study of potential environmental influences. Migration studies show 
that early (childhood) changes in geographical location influence the risk of MS, suggesting 
a role of environmental influences in the development of MS.110 The chances of identifying 
an unknown environmental factor X are higher in children as they are closer in time to the 
moment of exposure to this environmental influence (Figure 6).
Before we can advance in studying childhood onset in MS, a first necessity is a reliable 
diagnosis of MS in children. 
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figure 6. Putative environmental factor X and age at onset
It is hypothesized that a possible environmental factor X exist early in life, which is capable of influencing 
the risk of multiple sclerosis (MS) later in life. The chances of identifying such an environmental factor X are 
better in patients with childhood onset (dotted line) than in patients with adult onset (fixed line), because 
they are closer to the moment of exposure to this environmental influence. 
Adult MRI criteria for diagnosis of pediatric MS
In both adults and children the diagnosis of MS relies on dissemination in time and space 
(McDonald criteria).12 A definition of pediatric MS has been proposed in a consensus 
statement by the international pediatric MS study group (IPMSSG), depicted in Table 3.
A cross-sectional study in children with MS showed that only 50% of the children with 
MS fulfilled the Barkhof MRI criteria for dissemination in space.111 The Barkhof MRI criteria 
have been developed in adults to discriminate between MS lesions and atherosclerotic 
ischemic lesions. Children rarely have atherosclerosis, but they can have typical childhood 
diseases MRI abnormalities similar to MS. Because of a lack of clinical studies, implementing 
MRI criteria in children is a problem and especially in very young children, aged under ten 
years. This was also stressed in a review on MRI abnormalities in children with multiple 
sclerosis.107 It might be that the Barkhof MRI criteria for dissemination in space therefore are 
not suitable for the diagnosis of MS in children. 
Table 3. Proposed criteria for pediatric MS109
Multiple demyelinating episodes of the CNS fulfilling dissemination in time and space criteria
Dissemination in space criteria
•	 Two clinical locations separated in space (as in McDonald criteria)
•	 Barkhof MRI criteria can be used to fulfil dissemination in space criteria (see Table 1)
•	 Abnormal CSF (elevated IgG index and/ or oligoclonal IgG bands) in combination with ≥2 lesions on 
MRI
Dissemination in time criteria
•	 Two clinical episodes separated in time (as in McDonald criteria)
•	 New T2 or gadolinium enhanced lesions 3 months after the first demyelinating event (age ≥ 10 years)
A first episode compatible with ADEM cannot be considered as the first event of MS
CNS: central nervous system, CSF: cerebrospinal fluid, ADEM: acute disseminated encephalomyelitis,
MS: multiple sclerosis
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Distinguishing between MS and ADEM
In children, more frequently than in adults, a first demyelinating event cannot be 
distinguished from acute disseminated encephalomyelitis (ADEM).112-115 Several definitions 
for ADEM have been proposed.109,116 The IPMSSG introduced a definition of ADEM, shown in 
Table 4.109 When these typical ADEM cases have relapses, it becomes difficult to distinguish 
between ADEM and MS, because these cases then fulfil the McDonald criteria for 
dissemination in time and in space. For this purpose, the international pediatric MS study 
group introduced the terms recurrent ADEM and multiphasic ADEM (criteria are depicted 
in Table 5), thus separating these entities from MS.109 Because a first event compatible with 
ADEM cannot count as a first event in MS, problems arise when a first event compatible with 
ADEM is followed by an event not compatible with ADEM. Then neither the diagnosis MS 
nor the diagnosis recurrent/multiphasic ADEM can be made.
Clinical data on long term follow-up supporting these proposed criteria is lacking. This 
leads to uncertainty in patients, parents and physicians about prognosis and possible 
future therapeutic options after a first demyelinating event. It is crucial to determine which 
parameters reliably predict outcome after a first demyelinating event in children. 
Table 4. Proposed criteria for pediatric adeM109
All criteria must be fulfilled 
A first clinical event with a presumed inflammatory or demyelinating cause
Acute or subacute onset
Affecting multifocal areas of the CNS
Clinical: polysymptomatic
Encephalopathy
•					Behavioral change (confusion, excessive irritability)
•					Alteration in consciousness (lethargy, coma)
No other etiologies can explain the event
Event should be followed by (partial) improvement (clinical or radiological)
No history of a prior demyelinating event
New or fluctuating symptoms, signs or MRI findings occurring within 3 months of the inciting ADEM 
event are considered part of the acute event
Neuro-imaging shows focal or multifocal lesion(s), predominantly involving white matter, without 
radiological evidence of previous destructive white matter changes:
•	 Brain MRI (FLAIR, T2) shows large >1-2 cm lesions, that are multifocal, hyperintense and located 
supratentorial and infratentorial in the white matter or grey matter (basal ganglia/thalamus)
•	 In rare cases, brain MRI shows a large single lesion (>1-2 cm), predominantly in the white matter
•	 Spinal cord MRI may show confluent intramedullary lesions with variable enhancement
ADEM: acute disseminated encephalomyelitis, CNS: central nervous system, FLAIR: fluid attenuated 
inversion recovery
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Table 5. Proposed criteria for recurrent adeM and multiphasic adeM109
recurrent adeM Multiphasic adeM
New event of ADEM with a recurrence of the initial 
symptoms and signs, 3 or more months after the 
first ADEM event, without involvement of new 
clinical areas by history, neurologic examination or 
neuroimaging
ADEM followed by a new clinical event also 
meeting criteria for ADEM, but involving new 
anatomic areas of the CNS as confirmed by history, 
neurologic examination or neuroimaging
Event does not occur while on steroids, and occurs 
at least 1 month after completing steroid therapy
The subsequent event must occur 1) at least 3 
months after the onset of the initial ADEM event 
and 2) at least 1 month after completing steroid 
therapy
MRI shows no new lesions; original lesions may 
have enlarged
The subsequent event must include a 
polysymptomatic presentation including 
encephalopathy, with neurologic symptoms or 
signs that differ from the initial event (mental 
status changes may not differ from the initial 
event)
No better explanation exists The brain MRI must show new areas of 
involvement but also demonstrate complete or 
partial resolution of those lesions associated with 
the first ADEM event
ADEM: acute disseminated encephalomyelitis, CNS: central nervous system
Towards pediatric MRI criteria
Many studies on pediatric MS retrospectively investigated pediatric cases in adult cohorts.4,6,11 
Monophasic variants like ADEM or monophasic optic neuritis were not included in these 
studies. There is only one follow-up study in children with a broad clinical spectrum of first 
demyelinating events, like optic neuritis, transverse myelitis and ADEM. This French study 
showed that next to the Barkhof criteria the presence of lesions perpendicular to the corpus 
callosum and only well defined lesions on MRI (KIDMUS criteria) were of prognostic value 
for MS development (Table 6).114,117 The sensitivity of these KIDMUS criteria was very low 
(5%) in children aged under ten years. 
Recently, two new sets of MRI criteria have been proposed (Table 6). A first set 
of MRI criteria was developed to distinguish MS patients experiencing their first event 
from monophasic ADEM patients.118 A second set of criteria proposed modifications to the 
Barkhof MRI criteria in order to improve the diagnostic accuracy of these MRI criteria for 
MS in children. These criteria were initially designed to distinguish between MS (MRI at 
second MS defining attack) and other, non-demyelinating diseases (SLE and migraine).119 
These criteria have yet to be validated in an independent cohort.
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Table 6. Pediatric Mri criteria for diagnosing MS
KidMuS113-114
(1 out of 2) *
Callen: MS vs adeM criteria118
(at least 2 out of 3)
Callen: diagnostic MS 
criteria119
(at least 2 out of 3)
Lesions perpendicular to long axis 
of corpus callosum
Absence of a diffuse bilateral 
lesion pattern
≥ 5 lesions on T2-weighted 
images
The sole presence of well-defined 
lesions
Presence of black holes ≥ 2 periventricular lesions
≥ 2 periventricular lesions ≥ 1 brainstem lesion
* In the first publication both KIDMUS criteria were required114
MS: mulitiple sclerosis, ADEM: acute disseminated encephalomyelitis
Prediction of severity in pediatric MS
Apart from identifying prognostic factors for the diagnosis MS at onset of the disease, 
prognostic factors for early severity are necessary. Knowledge of such prognostic parameters 
may help selecting those children with a poor prognosis for future treatment trials. A 
childhood-onset MS potential index for early severity has been proposed.120 This index is 
based on the presence of one or two of the KIDMUS MRI criteria, female gender, a short 
interval between the first and the second (MS-defining) attack, absence of encephalopathy 
and progressive disease course. This severity score has yet to be validated in another 
independent pediatric cohort.
iV. SCoPe and ouTline of ThiS TheSiS
This thesis focuses on two topics in MS: pregnancy and young age at onset. The main 
objective of our studies on MS and pregnancy was to identify possible underlying biological 
mechanisms of MS disease amelioration during pregnancy. We also aimed to asses in more 
detail the disease course including quality of life, and to find and confirm risk factors for 
postpartum relapse. Our main objective in the studies presented in this thesis on onset of 
MS in children was to improve the difficult diagnostic process in children.
 To study pregnancy in MS patients we performed a longitudinal, prospective study in 
which ambulant relapsing remitting MS patients with a childwish or that were pregnant, 
were recruited at the Rotterdam MS Center, ErasMS. The study was designed to include 
patients preconceptionally, but inclusion was also allowed during pregnancy. All MS 
patients were seen at 10–12 weeks and 28–30 weeks of pregnancy, and at 4–8 weeks after 
delivery. MS patients were also invited at a time point at least 9 months after delivery, 
without clinical infection or recent disease activity.  
To study onset of MS in children we performed a nationwide study on early prognostic 
factors after a first demyelinating event. Children under the age of 16 were included with 
an attack compatible with a demyelinating disease of the CNS in the period 1990-2007. 
Patients were identified by members of the Dutch Study Group on childhood MS and ADEM. 
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All major pediatric neurology centres in hospitals in the Netherlands participated with 
complete geographical coverage of the Netherlands.
The studies concerning MS and pregnancy are described in chapter 2. The studies 
concerning onset of MS in children are described in chapter 3.
In chapter 2.1 we report on clinical and self report scales in women with MS, before, during 
and after delivery. Quality of life during pregnancy was compared with healthy pregnant 
women. Possible risk factors for post partum relapse are discussed. Chapter 2.2 shows data 
on the effect of breastfeeding in women with MS. Chapter 2.3 provides data on the possible 
use of the chemokine interleukin 8 as a biomarker for postpartum relapse. 
In chapter 2.4 we describe a genome wide RNA expression study in monocytes during 
pregnancy. We set out to identify activation or depression of immunological pathways 
in monocytes that might explain the amelioration of MS during pregnancy. In chapter 
2.5 we focus on highly relevant T cell subsets. We hypothesized that frequency of Treg 
and Th17 cells in peripheral blood were altered during pregnancy, explaining the clinical 
improvement during pregnancy. In chapter 2.6 we investigate serum levels of leptin during 
pregnancy and the possible use of leptin as a biomarker for postpartum relapse.  
In chapter 3.1 we report on a large national multicentre study on prognostic factors after 
a first demyelinating attack. We aimed to identify clinical, radiological and CSF factors 
predicting development of MS after a first inflammatory demyelinating attack in children. 
In chapter 3.2 we set out to find clinical and radiological factors able to predict an early 
relapse after the diagnosis in children. In chapter 3.3 we compare four current sets of MRI 
criteria in our pediatric cohort and determined which are the most useful in clinical practice 
for distinguishing ADEM from MS.
In the discussion the observations from the studies in chapter 2 and 3 are summarized 
and discussed in relation to current literature. Recommendations for further research are 
described.
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abSTraCT 
Relapse rate is decreased during pregnancy in multiple sclerosis (MS). Risk for postpartum 
relapse is increased in the first 3 months after delivery. We aimed to study clinical course of 
MS around pregnancy, using clinical as well as self-report scales, including data on quality of 
life (QoL), and to identify clinical factors predisposing for postpartum relapse. We performed 
a prospective, longitudinal study among 35 MS patients and 20 controls. In patients we 
assessed expanded disability status scale (EDSS), the Guy’s neurological disability scale 
(GNDS) and the multiple sclerosis impact scale 29 (MSIS-29). In patients and controls we 
assessed the MOS 36 item short form health survey questionnaire (SF36), consisting of eight 
domains. The previously described surge in relapses after delivery was also obvious in this 
study (p = 0.005). At group level EDSS and MSIS-29 did not show overt fluctuations over time. 
The GNDS, however, improved during the third trimester, compared to the first trimester (p 
= 0.003). A concomitant improvement in the SF36 domains vitality (p < 0.001) and general 
health (p = 0.001) was found in patients. At the final visit, at least 9 months after delivery, 
no worsening of EDSS, GNDS, MSIS-29 or SF36 was observed compared with the (for MS, 
beneficial) third trimester. Duration of disease, relapses in the year preceding pregnancy or 
relapses during pregnancy were not associated with postpartum relapse. QoL is improved 
during pregnancy. Although relapse rate was increased directly after delivery, in the mid 
long term after delivery no adverse effects of pregnancy on MS were found.
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inTroduCTion
The clinical debut of multiple sclerosis (MS) in women is often during the childbearing 
years.1 Factors associated with family planning are a major concern when having a chronic 
disease like MS. Pregnancy has a known ameliorating effect on the disease activity.2 In the 
third trimester the relapse rate is decreased by around 70% compared to the year preceding 
pregnancy. Yet in the first 3 months after delivery, one in every three women has a relapse.2-3 
 Several questions arise when counselling women with MS who want to become 
pregnant. First, the timing of a postpartum relapse, early after delivery, may unfavourably 
influence daily care for the newborn infant. Prediction of a postpartum relapse would be 
most helpful in order to anticipate on this postpartum relapse. A previous study showed 
that the following three clinical factors were found to be predictive of a postpartum relapse: 
(1) the number of relapses in the year preceding pregnancy, (2) the number of relapses 
during pregnancy, and (3) the duration of disease.3 These findings have not been validated 
in an independent prospective cohort. 
 Second, the clinical data in the few available studies on pregnancy and MS are limited to 
the expanded disability status scale (EDSS) and relapse rate. No quality of life (QoL) issues or 
self report scales were addressed in these studies. Next to insight in disease course in terms 
of disability and attack frequency, also better insight in QoL during and after pregnancy is 
necessary to inform women with MS who want to become pregnant. 
 Third, it has been shown that the relapse rate declines after a peak in the first 3 months 
after delivery. Nine months after delivery the relapse rate is comparable with the relapse 
rate in the year preceding pregnancy. Whether QoL at that time has improved or worsened 
is unknown. 
 The aims of this prospective and longitudinal study were not only to confirm data on 
EDSS and relapse rate, but also to address clinical course and outcome by using clinical 
scales as well as self-report scales including QoL parameters. Our second goal was to identify 
or confirm clinical risk factors predisposing for postpartum relapse. 
MaTerialS and MeThodS 
Participants and procedures 
The Rotterdam Study on Pregnancy in MS was performed at ErasMS, the MS Centre at 
Erasmus MC. Ambulant MS patients, with a relapsing remitting disease course, were invited 
to participate. Control patients were recruited from the out-patient clinic of Obstetrics at 
the Erasmus MC. Exclusion criteria for MS patients and controls were recurrent abortion, 
hypertension, diabetes mellitus or other systemic diseases. The study was designed to 
include patients preconceptionally, but inclusion was also allowed during pregnancy. 
Inclusion of all controls occurred during the first trimester. All MS patients and controls were 
seen at 10–12 weeks and 28–30 weeks of pregnancy, and at 4–8 weeks after delivery. MS 
patients were also invited at a time point at least 9 months after delivery, without clinical 
infection or recent disease activity. 
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 Data on maternal age, disease duration, and parity were collected at the first visit. 
Data on gestational age at delivery, multiple pregnancy, (pre)eclampsia, delivery, birth 
weight, and breastfeeding were collected at the last two visits. Data on relapse rate before 
pregnancy, during the three trimesters of pregnancy, and every 3 months in the first year 
after delivery were collected by interview at all these time points. The Guy’s neurological 
disability scale (GNDS), multiple sclerosis impact scale 29 (MSIS-29), and EDSS were assessed 
in patients at every visit. Both patients and healthy controls were asked to evaluate their 
health related QoL the month prior to evaluation using the MOS 36 item short form health 
survey questionnaire (SF36) at each visit. 
 This study was approved by the ethics committee of the Erasmus MC and all participants 
gave written informed consent.
Measurements
A relapse was defined as an episode of neurological disturbance for which causative lesions 
are likely to be inflammatory and demyelinating in nature and lasting more than 24 h.4 
Pseudo-relapse, meaning recurrence of previous signs and symptoms or fever-related 
worsening, was not considered as a relapse. Disease duration was measured from time of 
diagnosis. 
 The EDSS is the most widely used scoring system in MS and consists of findings of the 
neurological examination.5 The EDSS is an ordinal score that ranges from 0.0 (no disability) 
to 10.0 (death due to MS). The EDSS was scored at every visit by trained neurologists (RFN, 
TAMS, IAH, IAK, NJ, and RQH). 
 The GNDS consists of 12 items, all generating a score ranging from 0 (optimal health) to 5 
(poor health) with a summed maximum total score of 60.6 Items are cognition, mood, vision, 
speech, swallowing, lower and upper extremity function, bladder and bowel function, 
sexual function, fatigue, and one free item addressing another problem not yet contained in 
other items. 
 The MSIS-29 is a validated self-report scale consisting of two domains: physical health 
(20 items) and mental health (nine items).7-9 Both domains generate a score ranging from 
0 (optimal health) to 100 (poor health). The questions reflected on the 2 weeks preceding 
evaluation. 
 The SF36 is an instrument comprising four physical health domains and four mental 
health domains and has been used before in MS patients.10-12 The physical health domains 
are physical functioning, role physical functioning, bodily pain, and general health. The 
four mental health domains are social functioning, vitality, role emotional functioning, and 
mental health. For each domain a score is generated ranging from 0 (poor health) to 100 
(optimal health).
Statistical analysis
Differences in demographic and pregnancy characteristics and the SF36 between patients 
and healthy women were compared using the Student’s t test or Mann–Whitney U test 
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for continuous variables and chi-square for categorical variables. The same statistics were 
used for comparing characteristics of MS patients with and without a postpartum relapse. 
Relapse rate, clinical scales and self-report scales at the different time points were compared 
to the third trimester using a multiple measurements linear mixed model analysis. The 
third trimester was used as reference because maximal disease amelioration has been 
reported before at that time point.2 A p-value below 0.01 was considered significant. Data 
were analyzed using SPSS version 16.0.
reSulTS
Characteristics of the study population
Thirty-five women with MS and 20 controls participated in this study. Eighteen MS patients 
were included before pregnancy, 16 during the first trimester, and one during the third 
trimester. The mean time from inclusion to pregnancy in the 18 MS patients was 6 [standard 
deviation (SD): ±3.9, range 1–20] months. The mean time from delivery to the final visit in 
the MS group was 10 (SD: ±3.5, range 8–24) months. All controls were enrolled in the first 
trimester of pregnancy. 
 The controls were recruited from the outpatient clinic of Obstetrics in our hospital. The 
reasons for their referral were: previous cesarean section (six), history of cardiac problems 
(three, of which one also had twin pregnancy), medically assisted pregnancy (two), 
prematurity in previous pregnancy (two), previous post-natal depression (one), uterus 
duplex (one), epilepsy (one), twin pregnancy (one), metabolic disorder (one). Two women 
had no specific medical indication. 
 In the MS patients median disease duration was 4.0 (SD: ±4.0, range 0–13) years. Median 
EDSS was 1.5 (SD: ±0.8, range 0–4.0) in the first trimester (n = 34). Three MS patients received 
intravenous immunoglobulins directly after delivery with the aim to prevent possible 
relapses.13 One woman had already received corticosteroids as treatment for a postpartum 
relapse at the time of her first postpartum visit. At time of the final visit four patients used 
immune modulating drugs. 
 Data on pregnancy and birth outcome are presented in Table 1. A smaller proportion of 
women were nulliparous in the control group, compared to the MS patients. Breastfeeding at 
time of the first postpartum visit was more frequently observed in the MS group, compared 
to the control group. 
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Table 1: Maternal age and data on pregnancy and birth outcome
Patients
N=35
Controls
N=20
maternal age (±SD) (years) 31.2 (±3.8) 31.3 (±4.6)
nulliparous 71% 35%
cesarean section 14% 25%
assisted vaginal delivery (forceps/vacuum) 11% 5%
multiple (twin) pregnancy 0% 10%
gestational age at delivery (±SD) (weeks) 39.2 (±1.5) 38.1 (±2.7)
prematurity (<37 weeks of gestation)* 6% 5%
birth weight (± SD) (grams) * 3329 (±354) 3496 (±686)
small for gestational age ** 0% 0%
breast feeding 69% 40%
(pre)eclampsia 0% 0%
MS = Multiple Sclerosis, SD = standard deviation
* not including twin pregnancy
** small for gestational age is defined as birth weight under -2SD, using standardized intrauterine growth 
charts
Annualized relapse rate 
The annualized relapse rate is depicted in Fig. 1. After delivery a significantly increased 
relapse rate was observed during the first 3 months after delivery compared to the third 
trimester (p = 0.005). There was no significant difference in the annualized relapse rate in 
the year preceding pregnancy compared to the period 9-12 months after delivery. 
figure 1. relapse rate: before, during and after pregnancy in MS patients
Values represent the mean (±95%CI) annualized relapse rate. The third trimester was used as reference.
* P-value<0.01
PP = postpartum
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MS specific clinical and self report scales 
The MS specific clinical and self report scales are shown in Fig. 2. The GNDS showed a 
significant drop during the third trimester compared to the first trimester (p = 0.003) and 
the first postpartum visit (p = 0.001). We observed that about 85% of the mean drop in GNDS 
was mainly explained by three of the 12 items. These items concerned sexuality (31%), 
fatigue (28%), and a free item in which a complaint could be issued that was not addressed 
before in the other eleven items of the GNDS (26%). No differences were observed in the two 
domains of the MSIS-29 or the EDSS during the study. 
figure 2. edSS, GndS and MSiS29 scores: before, during and after pregnancy in MS
Values represent mean (±95%CI) scores of the EDSS, GNDS, MSIS-29 (physical and psychological subscale). 
The third trimester was used as reference.
* P<0.01 
PP = postpartum, EDSS = expanded disability status scale, GNDS = Guy’s neurological disability scale, MSIS-
29 = multiple sclerosis impact scale 29
Quality of life 
The SF36 was measured in both healthy controls and MS patients. The eight domains of 
the SF36 are shown in Fig. 3. MS patients reported an improvement in general health and 
in vitality during the third trimester compared to the first trimester (respectively, p = 0.001 
and p < 0.001). Healthy women reported an evident and significant increase in bodily pain 
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figure 3. Sf36 subscale scores: before, during and after pregnancy in MS and healthy women
Values represent mean (±95%CI) scores on the 8 subscales of the SF36: physical functioning, role physical 
functioning, bodily pain, general health, vitality, social functioning, role emotional functioning and mental 
health. The third trimester was used as reference. Scores range from 0 = poor health to 100 = optimal health.
* P-value <0.01, ** P-value <0.001 
PP = postpartum, SF36 = MOS 36 item short form health survey questionnaire
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at time of the first postpartum visit (p = 0.002) compared to the first trimester. The controls 
reported significantly more bodily pain than MS patients during the third trimester (p < 
0.001). A significant decrease in physical functioning in MS patients was found during the 
third trimester, compared to the first trimester (p = 0.002). Physical functioning improved 
significantly after delivery in both MS patients (p < 0.001) and healthy women (p < 0.001). 
Role physical functioning was decreased in the controls during the third trimester compared 
the first postpartum visit (p = 0.009). No differences were found in the domains social 
functioning, role emotional functioning and mental health. 
Postpartum relapse
Postpartum relapse occurred in 10 out of 35 MS patient (29%). One out of the three women 
treated with intravenous immunoglobulins after delivery had a postpartum relapse. The 
differences between the patients with and without a postpartum relapse are shown in Table 
2. Women with a relapse during pregnancy were more likely to also experience a relapse 
after delivery. This difference was not significant. At the final visit, we found no differences 
in all assessment instruments, between patients with and without a postpartum relapse. 
Both groups also showed no differences in all assessment instruments comparing their 
third trimester visit with their final visit. 
Table 2: Characteristics of patients with and without postpartum relapse
PP relapse
N=10
No PP relapse
N=25
P-value
maternal age (±SD) (years) 31.1 (±4.5) 31.3 (±3.6) 0.76
disease duration (±SD) (years) 2.9 (±2.0) 5.0 (±4.5) 0.36
relapse in year before pregnancy (%) 50% 44% 1.0
relapse during pregnancy (%) 30% 8% 0.13
nulliparous (%) 70% 72% 1.0
median EDSS first trimester (IQR) 2.0 (1.5-2.13) 1.25 (1.0-1.88) 0.01
assisted vaginal delivery or cesarean section (%) 30% 24% 1.0
SD = standard deviation, PP = postpartum, IQR = interquartile range, EDSS = expanded disability status scale
diSCuSSion
We here present prospective and longitudinal data on clinical and QoL parameters during 
pregnancy in MS. We found an increase in relapse rate after delivery, comparable with 
previous studies.2,3,14 We observed that this increase in relapse rate directly after delivery did 
not cause sustained adverse effects of pregnancy on MS in all used instruments at time of 
the final visit, 9 months or more after delivery. 
 During pregnancy and after delivery we observed no difference in the MS specific 
assessment instruments EDSS and the self report scale MSIS-29. A small improvement in 
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the GNDS was observed during the third trimester. Remarkably, this improvement in the 
GNDS was mainly explained by the domains concerning sexuality, fatigue, and the free 
item. Much in line with the decrease in fatigue is the improvement in the SF36 domains 
vitality and general health in MS patients during the third trimester. Contradictory to the 
amelioration of MS in the third trimester is the decreased health in the SF36 domain physical 
functioning in MS patients during the third trimester, compared with the first trimester 
and the first postpartum visit. On the other hand, decreased health in the SF36 domain 
physical functioning was also observed in controls during the third trimester compared to 
the postpartum visit. Therefore, this may be explained as a pregnancy effect and not MS 
related. 
 As described before15,16, we recorded no major adverse effects on birth outcome. A higher 
proportion of neonates small for gestational age in mothers with MS has been reported.15 
We also found a lower birth weight in the MS group, but this did not reach statistical 
significance. 
We also set out to validate several clinical risk factors for postpartum relapse that were 
previously identified.3 These were disease duration, number of relapses in the year preceding 
pregnancy and number of relapses during pregnancy. We were not able to validate these 
findings in our cohort. We did observe that women with a relapse during pregnancy more 
likely also had a postpartum relapse, although this was not significant. It is possible that our 
numbers were too small to demonstrate such effects. Interestingly, a recent study showed 
that exclusive breastfeeding was associated with a smaller chance of postpartum relapse.17 
We and others could not reproduce these intriguing findings.2,3,14,18,19 Taken together, we 
can conclude that, until now, there are no good clinical parameters predicting postpartum 
relapse. We, therefore, are in need of reliable biomarkers, able to predict a postpartum 
relapse. Interleukin 8 may be a candidate.20 
 Three points should be taken into account in respect to our data. First, the small numbers 
of patients and controls limited the conclusions of our study. We were not able to test for 
interaction effects and related measurements. In order not to make an over-interpretation 
we considered p-values under 0.01 to be significant and we used one visit as main reference. 
We chose the third trimester as main reference because maximal disease amelioration was 
reported at that time point.2,3 
 Second, the controls were referred to the outpatient clinic of Obstetrics mainly because 
of complications in previous pregnancies. Therefore, the chance of complications in the 
controls during these studied pregnancies and deliveries was increased. This may have 
influenced pregnancy outcome and QoL of the controls during and after pregnancy. It may 
likely explain why the controls reported more bodily pain than the women with MS during 
the third trimester. 
 Third, the participating patients in our study had a low EDSS, likely because we selected 
patients with a child wish. This low disability may have caused floor or ceiling effects 
limiting the ability of our measurement instruments to detect change. Especially the SF36 
is sensitive to floor and ceiling effects.21 It is possible that subtle differences in QoL were not 
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detected by the SF36. 
 We can conclude that in the mid-long term after pregnancy in MS patients EDSS, 
GNDS, MSIS-29, relapse rate and QoL are not unfavourably altered. We also showed that 
amelioration of disease course during pregnancy is not only defined by a decreasing relapse 
rate, but can also be regarded in terms of QoL, mostly appreciated in the SF36 domains 
vitality and general health. This underlines the necessity for including assessments of QoL 
when determining MS disease severity. The results from this study will help neurologists 
and MS-nurses counselling pregnant MS patients or MS patients with a child wish. 
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Breast-feeding and multiple sclerosis (MS) disease activity is controversial.1 Previous studies 
have not shown the effects of breastfeeding on risk of a postpartum relapse.2-3 In contrast, 
Langer-Gould et al.4 suggested that exclusive breast-feeding for at least the first 2 months 
after delivery protected against postpartum relapse. This finding is not supported by Airas 
et al.1, who found no protective effect of breast-feeding on the risk of postpartum relapse. 
We prospectively studied 35 women with relapsing-remitting MS, as described before.5 
Twenty-four (69%) patients breast-fed their babies for more than 2 months after delivery. 
Six out of these 24 (25%) who breast-fed their babies had a postpartum relapse in the first 
trimester after delivery, whereas 4 out of 11 (36%) who did not breastfeed their babies 
had a postpartum relapse (Fisher exact test: p = 0.68). Sixteen patients (46%) had a more 
severe disease course before pregnancy, defined as an annualized relapse rate greater than 
or equal to 1. Ten of these 16 (63%) patients breast-fed their babies, vs 14 out of 19 (74%) 
patients who had a benign disease course before pregnancy (Fisher exact test: p = 0.71). 
Total time of breast-feeding was shorter in the patients with a severe disease course (mean 
± SD: 14.8 ± 11.9 weeks) when compared with the patients with a benign disease course 
(mean ± SD: 21.7 ± 18.9 weeks), although this difference was not significant (Mann-Whitney 
U test, p = 0.38). Only 3 patients did not start or discontinued breast-feeding because of a 
necessity to commence disease-modifying drugs (DMD). In our cohort, disease activity 
preceding pregnancy was not associated with the decision to start and continue breast-
feeding. Therefore, this was not a confounder. Our results, although based on a relatively 
small cohort, confirm those of Airas et al. and others.1-3 They all show no protective effect 
of breast-feeding. This may dampen the promising findings by Langer-Gould et al.4 In the 
absence of clinical predictors of postpartum relapse2, predictive markers are needed. Serum 
level of Interleukin 8 may be a candidate.5
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abSTraCT
Pregnancy has an ameliorating effect on multiple sclerosis (MS), but directly after delivery 
the risk of a relapse is increased. The pro-inflammatory chemokine interleukin 8 is associated 
with disease activity. We aimed to investigate whether pregnancy-induced fluctuations of 
interleukin 8 correlate with periods of enhanced and diminished disease activity. Thirty-
six women with MS were prospectively studied before, during and after pregnancy. Serum 
levels of interleukin 8 were significantly decreased during the third trimester (p = 0.03). High 
first trimester serum levels of interleukin 8 were associated with a high risk of postpartum 
relapse (p = 0.007). These results help us to further understand the altered disease course 
during pregnancy.
First trimester IL-8 levels and postpartum relapse in MS
53
C
h
ap
te
r 
2
inTroduCTion
Pregnancy ameliorates the disease course of multiple sclerosis (MS) reducing disease 
activity by 70%.1 However, 30% of women with MS experience a postpartum relapse in 
the first 3 months after delivery.1 It is postulated that shifts from a pro-inflammatory to 
an anti-inflammatory immune environment and vice versa may be responsible for these 
fluctuations.2-3 A candidate mediator of these processes is the pro-inflammatory chemokine 
interleukin 8 (IL-8, CXCL8). IL-8 is a potent chemo-attractant involved in both attraction and 
infiltration of leucocytes (mainly neutrophils) at the site of inflammation.4 In MS patients, 
IL-8 expression is increased and is associated with increased disease activity.4-5 Chemokines 
play an important role for the maintenance of (early) pregnancy.6 No longitudinal studies 
on IL-8 levels in maternal serum in women with MS have been provided yet. Our aim was 
to assess whether pregnancy induces alterations in serum IL-8 levels and whether such 
alterations are associated with the risk of a postpartum relapse. 
PaTienTS and MeThodS
Patients
MS patients with a relapsing-remitting disease course and who were ambulant were 
recruited at the Rotterdam MS Center, ErasMS. Exclusion criteria were recurrent abortion, 
history of hypertension and diabetes mellitus. The study was designed to include patients 
pre-conceptionally though inclusion was also allowed during pregnancy. All MS patients 
were seen at 10–12 weeks and 28–30 weeks of pregnancy and at 4–8 weeks after delivery. 
Clinical follow-up data were available for more than 3 months after delivery in order to 
determine whether a postpartum relapse occurred. A relapse was defined as an episode 
of neurological disturbance for which causative lesions are likely to be inflammatory and 
demyelinating in nature and lasting more than 24 hours.7 MS severity was determined 
using the Expanded Disability Status Scale (EDSS).8 This study was approved by the ethical 
committee of Erasmus University and all patients gave written informed consent.
Serum IL-8 levels
Blood samples were taken at each visit between 10 and 12 am. Serum was stored at -80°C. 
Serum IL-8 levels were measured by enzyme-linked immunosorbent assay (ELISA), according 
to the manufacturer’s protocol (Sanquin, Amsterdam, The Netherlands). The detection range 
of the assay was between 1 and 240 pg/ml.
Data analysis
The Mann–Whitney U test was used for a comparison of continuous variables. The Fisher’s 
exact test was used for a comparison of dichotomized data. Serum levels of IL-8 at the 
different time points were compared using a multiple measurements linear mixed model 
analysis. P-values below 0.05 were considered significant. Data were analyzed using SPSS 
version 16.0.
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reSulTS
Patients and pregnancy outcome
Serum IL-8 levels were assessed in 36 pregnant women with MS of which 17 were included 
before pregnancy (mean 6 months (SD: ±3.8) before pregnancy), 17 during the first trimester 
and 2 during the third trimester. In one MS patient the third trimester visit was lacking. 
Mean MS disease duration before the start of the studied pregnancy was 4.5 (SD: ±3.8) years. 
Mean maternal age was 30.9 (SD: ±3.7) years. Median EDSS measured at first trimester visit 
was 1.5 (range 0–4.0). None of the patients received medication except for three patients who 
received intravenous immunoglobulins directly after delivery, with the aim of protecting 
against possible exacerbations.9 Mean duration of gestation was 39.1 (SD: ±1.6) weeks. Mean 
birth weight was 3,369 (SD: ±413) grams. None of the children were small for gestational age 
(defined as less -2 SD using standardized intra-uterine growth charts). Eleven women with 
MS (31%) had a relapse in the first 3 months after delivery.
Serum IL-8 levels
During the third trimester of pregnancy a significant decrease was observed, compared with 
the first trimester (Figure 1A). First trimester serum levels were higher in the group with an 
eventual postpartum relapse compared with the group that did not (p = 0.015; Figure 1B). 
The same held true for the serum levels of IL-8 before pregnancy, although these numbers 
were small for statistical comparison (data not shown). In order to compare women with 
high and low IL-8 levels in the first trimester we digitomized the group using the median 
first trimester levels of IL-8 (=6.8 pg/ml). We observed that serum IL-8 levels during the 
first trimester below 6.8 pg/ml were highly predictive of being relapse free in the first 3 
months after delivery; 1 out of 17 (6%) patients with serum IL-8 levels below 6.8 pg/ml had 
a postpartum relapse versus 9 out of 17 (53%) with serum IL-8 levels above 6.8 pg/ml (p = 
0.007). Using this cut-off value results in a sensitivity of 90% (9/10) and specificity of 67% 
(16/24).
diSCuSSion and ConCluSion
Here we have presented a longitudinal and prospective study on serum levels of IL-8 during 
and around pregnancy in MS patients. We found that during pregnancy IL-8 levels were 
decreased in the third trimester when compared with the first trimester. This drop in the 
pro-inflammatory chemokine IL 8 is compatible with the lower disease activity during the 
third trimester. Moreover, we found that serum levels of IL-8 at the time of the first trimester 
were associated with postpartum relapse in the first 3 months after delivery. From a clinical 
point of view the possibility to predict post partum relapses would be welcome, at least 
for practical reasons such as the ability to identify those patients who would or would 
not benefit from prophylactic treatment such as intravenous immunoglobulins.9 Clinical 
parameters studied before proved to be insufficient predictors of postpartum relapse at 
First trimester IL-8 levels and postpartum relapse in MS
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the individual level.10 Using our, arbitrarily chosen, cut-off level of first trimester IL-8 levels 
resulted in a, possibly clinically useful, negative predictive value of 94%. Yet the low positive 
predictive value of 53% and our relative small numbers limit the clinical use of IL-8 as a 
predictive parameter in this setting for now.
figure 1. (A) Serum levels of IL-8 in MS patients before pregnancy, at time of the first and third trimester 
and 4-8 weeks postpartum. Horizontal lines represent means. (B) Serum levels of IL-8 in MS patients with 
and without a postpartum (PP) relapse and without at time of first trimester. Horizontal lines represent 
means.
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Background: During the third trimester of pregnancy multiple sclerosis (MS) disease activity 
is reduced. It is not fully understood which factors mediate this disease amelioration. 
Objective: To study alterations of the monocyte transcriptome during pregnancy in MS 
patients, using a genomewide approach to identify differentially regulated genes.
Methods: Women with MS and healthy controls were longitudinally studied, including a 
visit before pregnancy. 
Results: RNA-microarray analysis was performed in six patients. We found a significant 
increase of CD64 (Fc gamma receptor 1a, FcgR1a) during the third trimester compared 
with baseline, confirmed by RT-PCR in a group of ten patients. Analysis with Ingenuity 
software was performed using all genes expression of which was altered at least 1.5-fold 
in at least five out of six patients. Major networks that were altered during MS pregnancy 
were: cell-to-cell signalling and interaction, immune response, and cell signalling. From the 
genes selected for Ingenuity analysis, seven additional candidate genes, selected for their 
biological interest, were tested using RT-PCR in ten patients with MS and nine controls. We 
found an increased expression of JAK2 and STAT1 directly postpartum in patients with MS 
and in controls.
Conclusion: The increased CD64 expression during pregnancy is indicative of enhanced 
innate immune functions.
The monocyte transcriptome during pregnancy in MS
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inTroduCTion
In women, the debut of multiple sclerosis (MS) often occurs during childbearing years.1 
MS is considered to be a T-cell driven autoimmune disease.2 Disease activity is thought to 
be mediated by CD4+ Thelper (Th) cells producing pro-inflammatory cytokines, such as 
IFN-γ and IL-17. T-cell subset differentiation and T-cell reactivity in the central nervous 
system (CNS) is driven by antigen presenting cells (APC) like dendritic cells and monocytes/
macrophages.2 
 Pregnancy has an ameliorating effect on disease activity, especially during the third 
trimester with a 70% decrease of the annualized relapse rate. However, in the first 3 months 
after delivery disease activity rebounds and one in every three women with MS experiences 
a relapse.3 The underlying biological mechanisms of pregnancy as an important biological 
modifier of MS disease course remain unclear. Multiple mechanisms have been suggested. 
Placental factors like trophoblast cells expressing HLA-G class and production of IL-10 
and indoleamine-2,3-dioxygenase (IDO) have been reported.4 Furthermore, a well-known 
proposition is that adaptive immunity during pregnancy skews from a pro-inflammatory 
phenotype towards an anti inflammatory phenotype.4-5 Although one could expect pregnant 
women to have an increased number of infections, because of the immune-suppressive 
environment, there is no significant increase in the number of infections, nor evidence for 
an altered pattern of pathogens. It has been hypothesized that innate immunity is activated 
to compensate for the presumed decrease in adaptive immunity.4,6-7 This activation 
includes expanded numbers and activity of monocytes/macrophages, key players in innate 
immunity.8 The activation of monocytes/macrophages has not been explored during MS 
pregnancy thus far. Hence, the aim of our current study was to identify genes differentially 
expressed over the course of pregnancy and postpartum.
MaTerialS and MeThodS
Patients and healthy controls
Patients with MS and a relapsing–remitting disease course and who were ambulant were 
recruited at the Rotterdam MS Centre, ErasMS. Healthy control donors were recruited 
from our outpatient clinic of obstetrics. Exclusion criteria were recurrent abortion, history 
of hypertension and diabetes mellitus. The study was designed to include patients 
preconceptionally and inclusion was also allowed during pregnancy. Inclusion of all healthy 
controls occurred during the first trimester. All MS patients and controls were seen at 10–12 
weeks and 28–30 weeks of pregnancy and at 4–8 weeks postpartum. The occurrence of a 
clinical infection was determined by anamnesis at the study visit, next to questionnaires. 
 A relapse was defined as an episode of neurological disturbance for which causative 
lesions are likely to be inflammatory and demyelinating in nature and lasting more than 
24 h.9 MS severity was determined using the Expanded Disability Status Scale (EDSS).10 This 
study was approved by the ethics committee of the Erasmus University Medical Center and 
all patients gave written informed consent. 
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Blood samples 
Blood samples were taken at each visit between 10 am and 12 noon. Peripheral blood 
mononuclear cells (PBMC) were isolated using CPT cell preparation tubes (Becton Dickinson, 
Breda, The Netherlands) and stored in liquid nitrogen until use. 
Microarray analysis 
CD14+ APC were selected using CD14 microbeads (Miltenyi, Utrecht, The Netherlands). 
Total RNA isolation from CD14 positive and negative cell fractions was performed using the 
RNeasy Mini Kit (Qiagen, Venlo, The Netherlands) following the manufacturer’s procedures. 
Subsequently RNA was quantified using the Nanodrop spectrophotometer (Isogen Life 
Science, IJsselstein, The Netherlands). Integrity of the RNA was assessed by bioanalyser 
(Agilent, Amstelveen, The Netherlands) analysis. Next, 1mg RNA was amplified and 
biotin labelled using the IVT labelling kit (Affymetrix, Santa Clara, CA, USA) following the 
manufacturer’s protocol. Human gene chip probe array (Affymetrix) analysis was performed 
according to the procedures provided by the manufacturer. Genechip probe arrays (Human 
genome U133 plus 2.0) were hybridized with 15mg cRNA at 45°C for 16 h. Scanning of the 
genechip arrays was performed using the Genechip Scanner 3000G7 (Affymetrix) at 570 
nm. Results were analyzed by using the Genechip Operating Software (Affymetrix). 
RNA and RT-PCR analysis 
RNA isolation from CD14+ cells was performed by using the GenElute Mammalian Total 
RNA Miniprep Kit (Sigma, Zwijndrecht, The Netherlands). RNA samples were DNAse I treated 
to remove contaminating DNA (Invitrogen, Breda, The Netherlands). Using 0.5 mg RNA as 
template, copy DNA (cDNA) was reverse transcribed by using Superscript II (Invitrogen). 
Primers and probes were selected by using the Universal ProbeLibrary Assay Design 
Center (Roche, Almere, The Netherlands). To determine target gene mRNA expression, real-
time quantitative reverse transcription PCR was performed using TaqMan technology as 
described previously. GAPDH mRNA levels were measured as a control to normalize for RNA 
input. An Applied Biosystems 7900 Sequence Detector was programmed for the initial step 
of 2 min at 50°C and 10 min at 95°C, followed by 40 thermal cycles of 15 s at 95°C and 1 
min at 60°C. For calculation of mRNA expression levels Ct values per gene were applied to 
standard curves, generated for each specific gene of interest.
Data analysis
The percentage of present calls, noise, background, and on-chip housekeeping gene controls 
all indicated a high quality of samples and an overall comparability. Probe sets that were not 
present (according to Affymetrix MAS5.0 software) in any of the Genechips were omitted 
from further analysis. Raw intensities of the remaining probe sets of each chip were log2 
transformed and normalized using quantile normalization. After normalization, the data 
were back-transformed to normal intensity values. Data analysis was carried out using 
excel and OmniViz software, version 3.6.0. Differentially expressed genes were identified 
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using statistical analysis of microarrays (SAM) or by calculating fold changes (at least 1.5-
fold up or down in at least five out of six patients). Functional annotation of the results was 
done using Ingenuity Pathway Analysis (Ingenuity, Mountain View, CA) (www.ingenuity.
com). RNA levels at the various time points were compared using a multiple measurements 
linear mixed model analysis. Bonferroni correction for multiple testing was applied. For 
comparison of continuous variables the Mann–Whitney U-test was used. For comparison 
of dichotomized data the Fisher’s exact test was used. P values below 0.05 were considered 
significant. Data were analysed using SPSS version 16.0.
reSulTS
Patients and healthy women
RNA microarray analysis was performed on six women with MS, comparing the baseline 
(before pregnancy) visit with the third trimester visit. Validation of the microarray data by 
RT-PCR was performed for 10 women with MS and nine healthy women. In four out of these 
10 women with MS both RNA microarray and RT-PCR were performed. None of the women 
with MS had a relapse, a clinical infection or additional medication during the study course. 
Demographic and clinical data are depicted in Table 1. No significant differences between 
the women with MS and healthy women were observed, except that women with MS were 
more often nullipara. None of the women with MS or healthy women had (pre-)eclampsia. 
Table 1. Patients and healthy women, demographic and clinical data
MS patients n=6
RNA microarray
MS patients n=10
RT-PCR
Healthy n=9
RT-PCR
P Value*
mean maternal age (years ±SD) 33.0 (± 3.0) 32.3 (± 3.7) 32.6 (± 2.0) n.s.
median EDSS (range) 1.5 (0-2.0) 1.5 (0-2.0) n.a. n.s.
nullipara 5/6 10/10 5/9 0.033
caesarean section 1/6 3/10 4/9 n.s.
mean duration of gestation 
(weeks ±SD)
39.0 (±1.6) 39.4 (±1.4) 38.1 (±2.6) n.s.
breastfeeding at last visit 5/6 6/10 4/9 n.s.
* MS patients n= 10 (RT-PCR) compared to healthy women n=9 (RT-PCR). Mann-Whitney U test and Fisher’s 
exact test were used.
RNA microarray comparison of baseline and third trimester
Using a very stringent statistical analysis for microarray (SAM), we found a significant 
increase in expression of CD64 (Fc gamma receptor 1a) during the third trimester compared 
to the baseline (before pregnancy) visit. Also an increase in ankyrin repeat domain 22 
(ANKRD22) expression was observed. 
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RT-PCR validation of increased CD64 expression 
The significant increase in CD64 expression during the third trimester of pregnancy detected 
by microarray analysis was confirmed by RT-PCR. The primer set used is listed in Table 2. 
An increase in mRNA expression was observed during the first trimester, although not 
significant, and during the third trimester (p<0.05) when compared to the baseline (before 
pregnancy) visit (p<0.05) (Figure 1). For healthy women no baseline sample was available, 
so comparison of the baseline with third trimester was not possible. A significant increase 
of CD64 expression was observed directly post partum (p<0.05) in both MS patients and 
healthy women.
Table 2. Primer sets and function of genes used for rT-PCr
Gene name accession number Primer sequelnces (5’ to 3’)
exiqon 
probe nr
Gene function
Cd64 (NM_000566) F: tgggaaagcatcgctacac
R: gcactggagctggaaatagc
18 high affinity receptor to 
the Fc fragment of IgG3> 
IgG1>IgG4> IgG2
Stat 1 (AY865620) F: cagtgggtagacacaaaatgga
R: cagaacaagaagagtatggcagaa
2 Cytokine receptor 
signalling
JaK2 (NM_004972) F: ggtgaaagtcccatattctggt
R: aggccacagaaaacttgctc
50 Cytokine receptor 
signalling
Cd38 (NM_001775) F: cagcaacaaccctgtttcagt
R: ttgagcatcacatggaccac
27 NAD glycohydrolase, cell 
signalling
il-8 (NM_000584) F: agacagcagagcacacaagc
R: atggttccttccggtggt
72 Neutrophil chemo-
attraction
PTX3 (NM_002852) F: gcggtgctagaggagctg
R: ggaataaaatagctgtttcacaacct
23 Attenuation of 
neutrophil recruitment
CXCl2 (NM_002089) F: catcgaaaagatgctgaaaaatg
R: ttcaggaacagccaccaata
69 Neutrophil chemo-
attraction
figure 1. Cd64 expression in MS patients and healthy women using quantitative rT-PCr
RNA expression compared to GAPDH (ratio: compared to first sample). Horizontal lines represent medians.
Multiple measurements linear mixed model analysis. * P< 0.05.
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Pathway analysis of microarray data
To further unravel potential disease ameliorating mechanisms Ingenuity analysis was 
applied. Therefore all genes that were increased or decreased at least 1.5-fold in five or six 
out of the six patients studied during the third trimester were entered into the Ingenuity 
program. Sixty-nine transcripts were found, of which 42 genes could be used in Ingenuity for 
network analysis. Twenty-one genes were involved in cell-to-cell signalling and interaction. 
Other molecular and cellular functions included: immune response (20 genes) and cell 
signalling (16 genes). The major networks found to be involved using Ingenuity web-based 
software are described in Table 3. 
Table 3. Biological networks identified by Ingenuity analysis
Network Genes in network Top functions
1 Akt, Apyrase, BDKRB1, CEACAM6, CXCl2↓, EDG2, ereG↓, 
fCGr1a↑, G alphai, GaS6↑, GbP1↑, GPSM1↓, IFNZ, IL1, il8↓, 
IL18BP, Il1r, il1r1↓, IRAK4, JaK2↑, Mapk, P2ry12↑, Pdgf, PI3K, 
PMl↑, PTX3↓, Rac, Ras, rGS1↓, SCYE1, SerPinb2↓, STaT1↑, 
STAT5a/b, Tgf beta, TYRO3
Cell signalling; cell-to-cell 
signalling and interaction; 
hematological system 
development and function
2 bre↓, C3, C7orf16↓, Cd38↑, CD44, Cd1C↓, CFB, CFH, CR1, 
CXCl2↓, ePb41l3↑, FCER2, fCer1a↓, FPR1, GM2A, IGKC, iGl@↓, 
IL13, IL25, il1r1↓, IL1R2, IL8RB, INDO, MS4A2, oaS3↑, olr1 
(includes eG:4973)↓, PECAM1, Pla2G7↓, PP2A, SLPI, SorT1↑, 
TNF, TNFAIP6, TPT1, WNT5A
Cellular movement; immune 
response; hematological 
system development and 
function
3 ALOX5, BTG1, CD40LG, CDKN1A, DDB2, ddef2↑, EBI3, ebi2 
(includes eG:1880) ↓ ECGF1,FANCC, fer1l3↑, FGF13, GbP1↑, 
HOXA5, IFI6, IFI35, ifi44↑, ifi44l↑, IFITM1, IFNA5 (includes 
EG:3442), IFNE1, il1r1↓, INDO, Klf6↓, lGalS3bP↑, MST1, OAS1, 
PARP9, Pde4b↓, PKD1, PlaC8↑, SRC, STaT1↑, TNFAIP6, TP53
Cell-to-cell signalling 
and interaction; cellular 
function and maintenance; 
immunological disease
Genes in bold are differentially expressed in the microarray analysis (at least 1.5 fold). Arrows indicate 
upregulation (↑) or downregulation (↓) during pregnancy in MS.
Candidate gene approach RT-PCR data
In addition to CD64, RT-PCR was performed on additional candidate genes. These candidate 
genes were selected from the top ten upregulated and top 10 downregulated genes found 
in the major networks identified by Ingenuity analysis. Based on their immunological 
function we selected IL-8 (CXCL8), CXCL2, CD38, signal transducer and activator of 
transcription 1 (STAT1), Janus kinase 2 (JAK2) and pentraxin 3 (PTX3). Gene functions and 
primer sets used are presented in Table 2. None of the genes studied were significantly 
altered in the third trimester, compared to the first visit. However, in patients with MS we 
observed a significant increase directly postpartum in JAK2 and STAT1 expression (p<0.05) 
compared to before pregnancy or to the third trimester, respectively. In healthy women we 
observed a comparable significant increase directly postpartum of both STAT1 and JAK2 
expression (p<0.01) compared to the first trimester (Figure 2). Expression levels did not 
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differ significantly between patients with MS and healthy women. Breast feeding was not 
associated with altered expression levels of the selected candidate genes.
figure 2. JaK2 and STaT1 expression in MS patients and healthy women using quantitative 
rT-PCr
RNA expression compared to GAPDH (ratio: compared to first sample). Horizontal lines represent medians.
Multiple measurements linear mixed model analysis. * P< 0.05, ** P<0.01.
diSCuSSion
Here we present a longitudinal study on differentially expressed genes during pregnancy 
in MS patients. Using a genomewide approach on a relatively small number of patients 
could have limited our results. Still, despite the small number of patients we were able to 
demonstrate up regulation of CD64 and ANKRD22 during the third trimester of pregnancy 
in MS patients. Since very little is known in the literature on the potential functions of 
ANKRD22, we did not further explore this gene in the current study. Increased expression 
of CD64 during the third trimester was confirmed by quantitative RT-PCR in women with 
MS. Enhanced CD64 expression in monocytes has been observed before in healthy pregnant 
women.11-14 Therefore there is little reason to suggest that our findings are MS specific, and 
instead pregnancy regulation of CD64 appears to be a general phenomenon. CD64 belongs 
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to the family of receptors for the Fc portion of immunoglobulins. CD64 is the high affinity 
receptor to the Fc fragment of IgG. It binds best to IgG3 and IgG1, followed by, with decreasing 
efficacy, IgG4 and IgG2 .15 CD64 is constitutively expressed at substantial levels by monocytes 
and macrophages.15-16 Ligation of Fc fragment of IgG to CD64 results in phagocytosis, 
respiratory burst and secretion of proinflammatory cytokines including IL-1 and IL-6.16 CD64 
knockout mice show impaired protection against bacterial infection.17 Monocyte activation, 
as found in sepsis, is associated with high CD64 expression.18 Also in systemic lupus 
erythematosus nephritis increased expression of CD64 on monocytes is a marker of systemic 
inflammation.19 Our results therefore support the hypothesis that innate immunity is more 
activated during pregnancy, likely as a means to prevent infectious complications.4,6–8 To 
further explore changes in monocyte RNA expression during pregnancy in MS we searched 
for genes expression that went up or down at least 1.5-fold in nearly all patients. The gene set 
derived from this approach was used in Ingenuity pathway analysis software. Assessment 
by Ingenuity identified the following major networks to be modulated in monocytes during 
the course of pregnancy: cell-to-cell signalling and interaction, immune response and cell 
signalling. These results further substantiate the hypothesis that monocyte activation 
is altered during MS pregnancy. In addition to CD64, we selected several more candidate 
genes (IL8, CXCL2, STAT1, JAK2, CD38, PTX3) to be studied in a larger patient group and in 
healthy pregnant women using quantitative RT-PCR. We found no statistically significant 
differences in expression of these genes of interest comparing the baseline sample with 
the third trimester sample in MS patients. There were no statistical differences between MS 
patients and healthy women. As baseline samples were not available in the healthy control 
group, full comparison with MS patients was limited. We observed a significant increase 
in expression of STAT1 and JAK2 in both MS patients and healthy women after delivery. 
The JAK/STAT pathway is crucial in cytokine signalling. Cytokine binding to its receptor 
causes activation of the intracellular JAK complex and downstream phosphorylation of STAT 
hereby regulating gene expression. Both JAK2 and STAT1 are crucial in IFN-γ signalling.20 
Increase in STAT1 expression in monocytes after delivery in MS has been observed before.21 
STAT1 is also essential for expression of T box transcription factor (T-bet) the latter being 
important for Th1 development and IFN-γ production.22 In monocytes T-Bet is expressed 
after stimulation with IFN-γ.23 In MS patients it has already been shown that STAT1 and 
T-bet expression in monocytes is increased at time of relapse24 while it is decreased after 
treatment with glucocorticoids.25 Also, in rheumatoid arthritis STAT1 expression is increased 
in synovial tissue compared to healthy controls indicating a pro-inflammatory role.26 A 
possible explanation of this rise in STAT1 activation is the postpartum increase of IFN-γ.27 
The postpartum increased expression of JAK2 and STAT1 can therefore, at least in part, 
be responsible for the increased disease activity after delivery in MS patients. A potential 
cause of this alteration in monocyte RNA expression during pregnancy could very well be 
oestrogens which reach peak levels during the third trimester. Oestriol in a dose of 8 mg/
day given in two periods of 6 months reduces magnetic resonance imaging (MRI) disease 
activity in MS28 and causes an upregulation of the anti-inflammatory cytokine IL-10 in PBMC 
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mainly because of increased numbers of CD64+ cells [29].29 In experimental autoimmune 
encephalomyelitis (EAE) mice treated with oestriol this amelioration of disease severity and 
increase in T-cell production of IL-10 was also observed.30 In guinea pigs treatment with 
oestriol increased expression of Fc gamma receptors in macrophages.31 In conclusion, we 
found that the monocyte transcriptome is regulated during pregnancy in patients with MS. 
These genes are related to: cell-to-cell signalling and interaction, immune response and cell 
signalling. This is most appreciated through CD64 expression which is strongly upregulated 
during the third trimester, indicating monocyte activation at this stage.
The monocyte transcriptome during pregnancy in MS
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PreGnanCy-induCed fluCTuaTionS in funCTional 
T-Cell SubSeTS in MulTiPle SCleroSiS PaTienTS
R.F. Neuteboom, E. Verbraak, A.F. Wierenga-Wolf, M. Van Meurs, 
E.A.P. Steegers, C.J.M. De Groot, J.D. Laman and R.Q. Hintzen
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abSTraCT
Background: During pregnancy, especially during the third trimester, multiple sclerosis (MS) 
disease activity is reduced. It is not known which factors mediate this disease amelioration.
Objective: To study whether the frequency of two important T-cell subsets, T-helper 17 
(Th17) and regulatory T-cells (Treg), is altered in relation to pregnancy-induced MS disease 
amelioration.
Methods: Each individual was tested longitudinally, after sampling of blood at timepoints 
before pregnancy, during the first and third trimester, and in the early post-partum period. 
Frequencies of Th17 cells were assessed after short (4 hours) re-stimulation of peripheral 
blood lymphocytes with PMA and ionomycin, followed by flow cytometry using CD4, 
CD45RO and IL-17A antibodies. To assess peripheral blood Treg frequencies, we used six-
colour flow cytometry with antibodies against CD3, CD4, CD25, CD127, FoxP3 and HLA-DR, 
to specifically identify Treg.
Results: Both MS patients (n=9) and controls (n=8) displayed unaltered Th17 frequencies 
during pregnancy. In contrast, circulating Treg frequency significantly decreased in MS 
patients (n=15) during the first and third (p<0.001) trimesters compared with the period 
before pregnancy. In the post-partum period, the frequency of circulating Treg again 
resurged back to near pre-pregnancy levels. In controls (n=15) comparable frequency kinetics 
were observed in that post-partum a significant increase in circulating Treg frequency was 
detected compared with the first (p < 0.001) and third (p = 0.012) trimester.
Conclusions: Third trimester amelioration is not related to the fluctuation of circulating 
Th17 cells. Furthermore, a paradoxical decrease of immunosuppressive circulating Tregs 
can be observed during this phase, both in MS patients and controls.
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inTroduCTion
Pregnancy has an ameliorating effect on the multiple sclerosis (MS) annualized relapse 
rate. In particular, during the third trimester a 70% decrease in disease activity is observed. 
However, after delivery disease activity rebounds and one in every three women experience 
a relapse within the first 3 months.1 MS is generally considered a CD4+ T-helper (Th) cell 
driven autoimmune disease.2 Recently an important proinflammatory T-cell subset, named 
Th17, has been implicated in MS disease activity.3 The Th17 subset is involved in the 
promotion of blood–brain barrier disruption and brain inflammation.4 Another important 
T-cell subset in MS are the immunosuppressive regulatory T cells (Treg), the central role 
of which has been demonstrated in the maintenance of self-tolerance in autoimmune 
animal models.5 The mechanisms underlying MS disease amelioration during pregnancy 
still remain unclear. Alterations in the frequency of Th17 cells and Treg could be involved 
in disease amelioration. Recently, the role of Treg during pregnancy has gained much 
attention6-7 because of their role in immunological tolerance to the fetus.8 Up to now 
thorough studies of Treg in MS pregnancy have been scarce and the available information 
has led to inconsistent conclusions.9-11 This may at least partly be explained by different 
flow-cytometric approaches. Treg identification has been much improved by detection of 
the forkhead box transcription factor p3 (FoxP3)12 and lack of expression of the IL7Ra chain 
(CD127).13 In view of their presumed critical roles in MS, alterations in systemic Th17 and 
Treg frequencies are potentially crucial to amelioration of the MS disease course. Hence, 
in a longitudinal study we analysed for the first time whether the frequency of Th17 cells 
is affected in MS patients and controls during pregnancy. Furthermore, we analysed the 
frequency of Treg during the course of pregnancy in MS using the recently established 
stringent Treg markers.
MaTerialS and MeThodS
Patients and controls
Ambulant MS patients with a relapsing–remitting disease course, fulfilling diagnostic 
criteria,14 were recruited at the Rotterdam MS Centre, ErasMS. Exclusion criteria were 
recurrent abortion, history of hypertension and diabetes mellitus. The study was designed 
to include MS patients pre-conceptionally. All MS patients were seen before pregnancy, 
at 10–12 and 28–30 weeks of pregnancy and at 4–8 weeks after delivery. MS severity was 
determined using the Expanded Disability Status Scale (EDSS).15 Healthy pregnant women 
were recruited from the outpatient obstetrics clinic at the Erasmus MC. They were also 
seen at 10–12 and 28–30 weeks of pregnancy and at 4–8 weeks postpartum. This study 
was approved by the ethics committee of the Erasmus University and all participants gave 
written informed consent.
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Blood samples and cell isolation
Blood samples were taken at each visit between 10 and 12 hours in the morning. Peripheral 
blood mononuclear cells (PBMCs) were isolated using CPT cell preparation tubes (Becton 
and Dickinson (BD), Breda, The Netherlands). After isolation PBMCs were stored in liquid 
nitrogen until use for flow cytometry.
Flow-cytometric analysis
For detection of Th17, PBMCs were re-stimulated with 50 ng/ml PMA, 500 mg/ml ionomycin 
and Golgi Stop (BD) for 4 h. Subsequently cells were stained using CD45RO-FITC (Dako, 
Heverlee, Belgium) and CD4-PerCP-Cy5 (BD). Next cells were fixed in 2% paraformaldehyde 
and permeabilized using 0.5% saponin (Sigma, Zwijndrecht, The Netherlands). Cells were 
subsequently incubated with anti-IL17A-PE (eBioscience, San Diego, CA). Flow-cytometric 
analysis was performed using a FACS Calibur (BD). Analysis of Treg was performed 
using: CD3-PerCP, CD4-AmCyan, CD25-PeCy7 (BD) and CD127-pacific blue (eBioscience). 
Intracellular staining for FoxP3 was performed using the FoxP3 Staining Buffer Set 
(eBioscience) in combination with anti-FoxP3-PE (BD). Analysis was performed using an 
LSRII flow cytometer (BD). Data were analysed using CellQuest Pro and FACS Diva software 
(BD) for Th17 and Treg subsets, respectively. Analysis of Th17 cells was performed by gating 
on CD4 followed by selection of the CD45RO+ (memory) cells. Within the CD4/ CD45RO+ 
gate IL-17+ cells were selected. For Treg analysis CD3+/CD4+ cells were selected followed by 
gating on FoxP3+/CD127low cells. To confirm Treg identity final selection was performed by 
gating back on CD25+/CD127low cells.
Statistical analysis
Comparison of continuous variables was performed using the Student’s t-test and Mann–
Whitney U test. Dichotomized data was analysed using the chi-squared or Fisher’s exact 
test. Data at the various timepoints were compared using a multiple measurements linear 
mixed model analysis. Data were analysed using SPSS version 16.0.
reSulTS
Clinical data
Treg frequency was studied in 15 women with MS and 15 healthy controls (Table 1). Median 
EDSS at baseline was 1.0 (range 0–2.5). Th17 frequency was analysed in a subset of nine 
women with MS and eight controls. Median EDSS was 1.0 (range 0–1.5). None of the patients 
had a relapse during the 4–8 week follow-up. Patients did not receive immune modifying 
medication at least 3 months before the first visit and during the study. Demographics and 
pregnancy outcome are depicted in Table 1. 
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Table 1. demographics and pregnancy outcome in MS patients and healthy controls
MS patients Healthy women
Treg (n=15) Th17 (n=9) Treg (n=15) Th17 (n=8) P Value*
mean maternal age (years ±SD) 31.5 0 (± 3.7) 30.7 (± 3.9) 31.8 (± 4.6) 30.6 (± 4.6) n.s.
median EDSS (range) 1.0 (0-2.5) 1.0 (0-1.5) n.a. n.a. n.a.
nullipara 12/15 6/9 7/15 2/8 n.s.
caesarean section 3/15 2/9 3/15 2/8 n.s.
(pre)eclampsia 0/15 0/6 0/10 0/8 n.s.
mean duration of gestation
(weeks ±SD)
39.3 (±1.2) 39.3 (±0.8) 37.9 (±2.3) 37.3 (±2.7) n.s.
breastfeeding at last visit 8/15 4/9 10/15 6/8 n.s.
* P value when comparing MS patients to healthy controls in both Treg and Th17 flowcytometric analysis 
(Mann-Whitney U test). n.s. = non significant; n.a. = not applicable; EDSS = expanded disability status scale. 
Th17 frequency is not altered during the course of pregnancy 
In order to analyse whether the pro-inflammatory Th17 cell subset in MS patients or 
controls is affected by pregnancy, the frequency of CD4+CD45RO+IL17A+ cells (Figure 1A) 
was assessed. No significant regulation of Th17 frequency was observed during pregnancy 
either in controls or MS patients (Figure 1B and C). Frequency of Th17 cells was similar for 
pregnant MS patients and controls.
A
figure 1. Th17 frequency is stable during pregnancy in MS patients and healthy controls. A) Number of IL-
17A (I) producing cells was determined by gating of CD4 and CD45RO double positive cells. In cells positive 
for CD4 alone (II) or negative for CD4 (III) very low or no IL-17A production was detected. B) Percentage of 
Th17 cells in MS patients before pregnancy, at first and second trimester and 4-8 weeks postpartum and C) 
in healthy controls during the 1st and 3rd trimester and after pregnancy. Horizontal lines represent means.
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Frequency of Treg is decreased during early and late pregnancy
To assess the effect of pregnancy on the frequency of Treg, cells were gated as shown in 
Figure 2A. Treg frequency in MS patients (Figure 2B) showed a significant decrease in 
frequency from before pregnancy compared with the first (p < 0.001) and third trimester (p < 
0.001). Shortly post-partum a significant increase was observed in comparison with the first 
(p = 0.005) and third trimester (p = 0.003) and Treg frequency approached pre-pregnancy 
level. For controls we found frequency kinetics (Figure 2C) comparable to MS patients, in 
that post-partum a significant increase in Treg frequency was observed in comparison with 
the first (p < 0.001) and third trimester (p = 0.012). When HLA-DR was used as a marker of 
recent Treg activation,16 similarly significant results were obtained (data not shown). Both in 
MS patients and controls FoxP3 expression level, as reflected by mean fluorescent intensity 
(MFI), significantly decreased from the first trimester towards the third trimester (MS: 3941 
± 1440 to 3295 ± 881, p = 0.001; and controls: 3577 ± 649 to 3235 ± 658, p = 0.033). In MS 
patients FoxP3 MFI levels significantly increased again to 3810±1176 (p = 0.003) compared 
with the third trimester. Similar to the Th17 subset highly comparable Treg frequencies and 
MFI levels were found in MS patients and controls.
A
B                                                                                    C
figure 2. Frequency of peripheral Treg is altered during pregnancy in MS patients and controls. A) Gating 
strategy for the identification regulatory T cells. Final number of cells in CD25/FoxP3 positive gate were used 
for further analysis incuding identification of MHCII positive Treg. B) Percentage of CD25+FoxP3+CD127low 
cells in MS patients within CD3+CD4+ gate before pregnancy, at first and second trimester and 4-8 weeks 
postpartum. C) Percentage of CD25+FoxP3+CD127low cells in healthy women within CD3+CD4+ gate, at 
time of first and second trimester and 4-8 weeks postpartum. Horizontal lines represent means. 
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diSCuSSion
We here present a longitudinal study analysing the frequency of Th17 and Treg in peripheral 
blood of MS patients versus controls during pregnancy. We hypothesized that alteration in 
the frequency of Th17 or Treg is involved in MS disease amelioration during pregnancy. 
We did not find any regulation in the frequency of Th17 cells in the peripheral blood of 
both MS patients and controls around and during pregnancy. This indicates that peripheral 
Th17 frequency is not influenced in MS during the course of pregnancy. Recently the Th17 
regulating microRNA miR-326 was suggested to be linked to disease severity.17 It would be 
attractive for future research to study how expression of miR-326, next to cytokines such 
as IL-17F or IL-22, would behave over time during pregnancy in MS. Another potential 
ameliorative mechanism is alteration in Treg frequency. In contrast to what we anticipated 
in women with MS the percentage of Treg declines during the first and third trimester in 
comparison with the sample taken before pregnancy. Postpartum (4–8 weeks) a significant 
increase in Treg frequency was observed compared with the first and third trimester. 
Although we lacked the before pregnancy time point for healthy controls it appears likely 
that the kinetics of peripheral Treg frequency is fully comparable to MS patients during 
pregnancy since frequencies during pregnancy as well as the postpartum increase were 
highly similar. In addition we also observed a significant decrease in FoxP3 MFI levels in both 
MS patients and controls from the first towards the third trimester. Previous studies have 
suggested quite disparate functions for Treg in pregnancy, since they have been described 
to either increase or decrease in frequency.9,18-20 These conflicting conclusions emphasize 
the need for additional studies analysing Treg kinetics during pregnancy using the recently 
refined Treg cell markers and stringent gating strategies, as were used previously.21-,22 Here 
we have shown that the Treg frequency is significantly decreased during the first and third 
trimester of pregnancy. Since both MS patients and controls demonstrate this reduction, 
the fluctuation in Treg frequency during pregnancy in MS patients appears to be part of 
normal pregnancy physiology. One potential disease-modifying mechanism could be the 
recent notice that Treg can also produce IL-17 under inflammatory conditions.23-24 As these 
Treg bear cell markers comparable to Th17 cells, we would have expected to find at least a 
minimal change in Th17 frequency during pregnancy. The systemic drop in Treg number 
may be explained by the importance of Treg in pregnancy outcome25 and their migration 
to the foetal–maternal interface.7 Furthermore, our finding of decreased numbers of Treg 
during the third trimester, the period associated with decreased disease activity, is of 
special interest as the use of depleting anti-CD25 antibodies decreases Treg number and 
nevertheless results in an amelioration of the MS disease course.22 Collectively, the data 
of the current study do not support the idea that peripheral blood Th17 and Treg cells are 
involved directly in MS disease course alteration during pregnancy.
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abSTraCT
Background: Disease activity in patients with multiple sclerosis (MS) is suppressed during 
pregnancy, whereas attack frequency increases after delivery. It is yet unclear, which 
immuno – endocrinological processes mediate these disease fluctuations. Leptin has been 
identified as a hormone that can influence inflammatory activity.
Objective: The aim of this study was to investigate whether pregnancy-induced fluctuations 
of serum leptin levels differed between patients with MS and controls and whether serum 
leptin levels correlate with periods of enhanced and diminished disease activity.
Methods: 36 Women with MS and 17 healthy women were prospectively followed during 
and after pregnancy. The MS group could be studied already at a timepoint before pregnancy. 
Serum leptin and soluble leptin receptor (SLR) levels were measured using enzyme-linked 
immunosorbent assay.
Results: Pre-pregnancy serum leptin levels were (mean ± SD) 22.9 ± 12.8 ng/ml in the MS 
group. These levels increased in the third trimester to 28.5 ± 15.0 ng/ml (P = 0.007). The third 
trimester serum leptin levels in healthy women were comparable, 29.4 ± 19.0 ng/ml. Serum 
leptin levels after delivery dropped to 18.5 ± 12.8 ng/ml in women with MS (P < 0.001) and to 
a lesser extend (22.0 ± 17.5 ng/ml) in healthy women (P = 0.04). SLR levels showed the same 
pattern. Remarkably, women with the highest relative decrease in serum leptin levels after 
delivery had more often a postpartum relapse (P = 0.008).
Conclusion: In women with MS, leptin increased during late pregnancy. A postdelivery drop 
in leptin levels was observed in both the MS and control group. The postdelivery drop was 
associated with the occurrence of postpartum relapse.
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inTroduCTion
Multiple sclerosis (MS) is the most common neurological disease in young adults, affecting 
women more than men.1 Disease presentation is often during childbearing years.1 
 Pregnancy has a known ameliorating effect on the disease activity, especially in the third 
trimester with a 70% decrease of the annualized relapse rate.2 However, in the first 3 months 
after delivery, disease activity rebounds and about one in every three women with MS has 
a relapse.2 The underlying biological mechanisms of this natural modifier of MS disease 
course remain unclear. It is proposed that adaptive immunity during pregnancy skews from 
proinflammatory toward anti-inflammatory immunity.3 Regulatory T-cells (Tregs), which 
are reported to have a protective role in autoimmune diseases such as MS, are altered during 
pregnancy.4 Recent findings also suggest an important role for natural killer (NK) cells.5 
 Hormonal factors are likely candidates for explaining this altered disease course during 
pregnancy. Estriol in a dose of 8 mg/day given in two periods of 6 months reduces magnetic 
resonance imaging disease activity in patients with MS.6 It causes an up-regulation of the 
anti inflammatory interleukin-10 (IL-10) in peripheral blood mononuclear cells mainly 
because of increased number of CD64+ cells (monocytes/macrophages).7 In experimental 
autoimmune encephalomyelitis (EAE), both estrogen and progesterone ameliorate disease 
severity and alter the profile of cytokine secretion toward a more antiinflammatory immune 
response.8-9 
 Next to sex steroids, leptin is another hormonal candidate. Leptin, first identified as an 
adipocyteproduced modulator of energy homeostasis, also has major effects on both innate 
and adaptive immune responses.10-13 Elevated serum leptins levels cause a proinflammatory 
immune response. In monocytes and macrophages, leptin promotes phagocytosis and 
proliferation together with production of proinflammatory cytokines such as IL-6, IL-12, 
and tumor necrosis factor-α (TNF-α).10-11 It induces chemotaxis of neutrophils and increases 
cytotoxicity of NK cells. Also adaptive immunity is shifted to a proinflammatory response.10 
There is evidence that leptin decreases the numbers of Tregs.12-13 In EAE, leptin is involved 
in both induction and progression of EAE.14 Administration of anti-leptin antibodies or 
soluble leptin receptors (SLRs) decreases disease severity in EAE.15 In patients with relapsing 
remitting MS, serum levels of leptin are increased.12 
 Leptin levels are elevated during pregnancy.16-18 So far no studies have addressed the 
relationship between leptin, the SLR, and altered disease course of MS during pregnancy. The 
aim of this prospective longitudinal study was to investigate whether pregnancy-induced 
fluctuation of serum levels of leptin and SLR differed between patients with MS and controls 
and whether serum leptin levels correlate with periods of enhanced and diminished disease 
activity. Our secondary goal was to study if these natural leptin fluctuations are associated 
with the occurrence of a postpartum relapse. 
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PaTienTS and MeThodS
Patients and healthy controls
MS patients with a relapsing remitting disease course and who were ambulant were 
recruited at the Rotterdam MS center, ErasMS. Healthy control patients were recruited 
from the outpatient clinic of obstetrics at the Erasmus MC. Exclusion criteria were 
recurrent abortion, history of hypertension, diabetes mellitus, or systemic diseases such as 
rheumatoid arthritis or systemic lupus erythematosus. The study was designed to include 
patients preconceptionally and inclusion was also allowed during pregnancy. Inclusion of 
all healthy controls occurred during the first trimester. All patients with MS and controls 
were seen at 10–12 weeks and 28–30 weeks of pregnancy and at 4–8 weeks after delivery. 
Data on age, ethnicity, parity, gestational age, twin pregnancy, (pre)eclampsia, birth weight, 
and breastfeeding were collected. 
 A relapse was defined as an episode of neurological disturbance for which causative 
lesions are likely to be inflammatory and demyelinating in nature and lasting more than 
24 hours.19 MS severity was determined using the expanded disability status scale (EDSS).20 
This study was approved by the ethics committee of the Erasmus university, and all patients 
gave written informed consent. 
Serum leptin and SLR levels
At each visit, blood samples were taken in the morning between 10 a.m. and 12 a.m. Serum 
was stored at −80 °C. Serum leptin levels were measured by enzyme-linked immunosorbent 
assay (ELISA), according to the manufacturer’s procedure (R&D systems, Abingdon, UK). The 
detection range of the assay was between 1.2 and 80 ng/ml. Serum LR levels were measured 
by ELISA according to the manufacturer’s procedure (R&D systems). The detection range of 
the assay was 0.3 to 20 ng/ml.
Data analysis
For comparison of continuous variables, the Student’s t-test and Mann–Whitney U test were 
used. For comparison of dichotomized data, the chi square or Fisher’s exact test was used. 
Linear regression as used for evaluating the relation between birth weight and leptin levels. 
Leptin levels at the different timepoints were compared using a multiple measurement 
linear mixed model analysis. Data were analyzed using SPSS version 16.0.
reSulTS
Patients and healthy controls
Thirty-six pregnant women with MS were studied, of which 17 were included before 
pregnancy (mean 6 months (SD ± 3.8) before pregnancy), 17 during the first trimester, and 
two during the third trimester. In one patient with MS, the third trimester visit was lacking. 
As a control group 17 healthy pregnant women were included, all first seen at time of the 
first trimester. 
Serum leptin levels during pregnancy in MS
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 Mean MS disease duration before the studied pregnancy was 4.5 years (SD ± 3.8). Median 
EDSS measured at first trimester visit was 1.5 (range 0–4.0). None of the patients received 
medication except for three patients who received intravenous immunoglobulins directly 
after delivery, with the aim to protect for possible exacerbations .21 Eleven women with MS 
(31%) had a relapse in the first 3 months after delivery. 
 Age at time of pregnancy was equally distributed in women with MS and the healthy 
women (Table 1). No statistical significant differences in women with MS and healthy in 
demographical and pregnancy outcome parameters were found, except that the women in 
the control group less often were primipara (Table 1). 
Table 1. data on pregnancy and outcome of women with MS and healthy women
women with MS
n=36
healthy women
n=17
P value
mean maternal age (years) (±SD) 30.9 (±3.7) 31.4 (±4.4) n.s.
  - maternal age 20-25 6 % 6 % n.s.
  - maternal age 25-30 36% 35 % n.s.
  - maternal age 30-35 33% 35 % n.s.
  - maternal age 35+ 11% 18 % n.s.
primipari 69 % 35% 0.019
non caucasian ethnicity 6% 6 % n.s.
twin pregnancy 0 % 12 % n.s.
(pre)eclampsia 0 % 0 % n.s.
cesarean section 14 % 24% n.s
mean duration of gestation (weeks) (±SD) 39.1 (±1.6) 37.9 (±2.8) n.s.
preterm (<37 weeks gestation) 6% 18% n.s.
mean birth weight (grams) (±SD)* 3369 (±413) 3476 (±690) n.s.
small for gestational age ** 0 % 0 % n.s.
breast feeding at last visit 61 % 47% n.s.
MS = multiple sclerosis, n.s. = not statistically significant, SD = standard deviation
* not including twin pregnancy
** small for gestational age is defined as birth weight –2SD, using standardized intra-uterine growth chart. 
Serum leptin and SLR levels before, during, and after pregnancy 
Serum levels of leptin during pregnancy in women with MS and healthy women are shown 
in Figure 1. Serum leptin levels (mean ± SD) in the women with MS before pregnancy were 
22.9 ± 12.8 ng/ml. First trimester serum leptin levels were 22.8 ± 13.6 ng/ml in women 
with MS and 28.4 ± 19.0 ng/ml in healthy women. In women with MS, serum leptin levels 
increased significantly during the third trimester of pregnancy to 28.5 ± 15.0 ng/ml (P = 
0.007, compared to pre-pregnancy visit and P = 0.012, compared to first trimester). In healthy 
women, serum leptin levels remained constant during the third trimester at 29.4 ± 19.0 ng/
ml. Serum levels of leptin after delivery significantly dropped to 18.5 ± 12.8 ng/ml in women 
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with MS (P < 0.001) and to 22.0 ± 17.5 ng/ml in healthy women (P = 0.036). Serum levels of 
leptin did not differ between women with MS and healthy women during pregnancy and 
after delivery. 
 SLR levels showed the same pattern as the leptin levels in serum in both patients with 
MS and healthy women. In women with MS, SLR levels (mean ± SD) were 15.3 ± 4.4 ng/ml 
before pregnancy. During pregnancy, these levels significantly rose to 21.1 ± 9.3 ng/ml (P 
< 0.001) during the first trimester and to 26.9 ± 8.9 ng/ml (P < 0.001) at time of the third 
trimester. After delivery, SLR levels significantly dropped to 19.1 ± 5.2 ng/ml (P < 0.001). In 
healthy women, we observed during the first trimester SLR levels of 20.7 ± 8.2 ng/ml, which 
significantly increased to 27.9 ± 10.9 ng/ml (P < 0.001) during the third trimester and after 
delivery significantly decreased to 19.4 ± 7.5 ng/ml (P < 0.001). 
 Comparison of primipara to multipara did not reveal significant differences in serum 
leptin or SLR levels before, during, and after pregnancy. Breastfeeding or a cesarean section 
was not associated with a change in serum levels of leptin. Serum leptin levels in the first or 
third trimester did not correlate with birth weight. 
figure 1. (A) Serum levels of leptin of MS patients before pregnancy, in the first and third trimester of 
pregnancy and 4-8 weeks post partum. (B) Serum leptin levels of healthy women in the first and third 
trimester of pregnancy and 4-8 weeks post partum. Horizontal lines represent means. 
* p<0.001, ** p=0.007, *** p=0.012, ***** p=0.036
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Serum leptin levels: predicting postpartum relapse?
Absolute serum leptin levels during and after pregnancy showed no association with 
the occurrence of a postpartum relapses. However, there were remarkably large inter-
individual differences in the drop of serum leptin levels after delivery compared with 
the third trimester, both in the MS and healthy group. To assess a possible association of 
these relative changes with postpartum attack frequency, we split the MS group into two 
subgroups, using the median percentual postpartum change of leptin (−40%) as a cutoff 
value (Figure 2). We observed that out of the 17 women with the most relative postpartum 
decrease in serum levels of leptin, nine (53%) had a postpartum relapse (Figure 2). However, 
out of the 18 women with the least relative decrease or even an increase, only two (11%) 
had a postpartum relapse (Figure 2). This indicates that a more substantial relative drop in 
serum leptin levels after delivery is associated with postpartum relapse (P = 0.008).
figure 2. Relative changes in serum leptin levels in MS patients comparing the third trimester (set at 0) 
with the post partum period. The group was digotomized using the median relative change (= –40%) as a 
cut-off. Difference in risk of postpartum relapse in these two groups was significant (p=0.008)
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diSCuSSion
This prospective study is the first to report longitudinal measurements of leptin before, 
during, and after pregnancy in patients with MS. We observed a significant increase in 
serum levels of leptin in women with MS during the third trimester when compared to 
baseline and first trimester samples. The decrease in leptin after delivery in the women 
with MS and in healthy women was comparable with earlier studies in healthy women.16-17 
 In contrast with the patients with MS, we observed no leptin increase during pregnancy 
in healthy women. As we had no sample before pregnancy in this group, we cannot rule out 
that leptin was already at its peak level at the first trimester measurement. On the exact 
timepoint of leptin peak level during pregnancy conflicting results have been reported, 
suggesting high variability.16-18 Possibly, in healthy women, serum levels were already 
increased before our measurement in the first trimester and, therefore, an increase during 
pregnancy would be missed. 
 It was noted that the healthy group contained less primipara women than the MS group. 
However, no significant difference between leptin serum levels between primipara and 
multipara was found, so it seems not likely that this difference influenced our results. 
 It has been demonstrated that children of mothers with MS have a lower birth weight.22 
We also observed a nonsignificant trend in the same direction. We found no relation between 
maternal serum leptin levels and birth weight in women with MS or healthy women, which 
was in line with an earlier study in healthy pregnant women.23 In addition, we confirm the 
absence of an association between maternal serum leptin levels and breastfeeding as is 
reported in healthy women.24 
 As an adipose tissue-derived energy homeostasis regulator, high serum levels are 
associated with a high body mass index (BMI) also during pregnancy.25 A shortcoming of 
our study is that we were not able to match women with MS and healthy women for BMI, 
thus limiting direct comparison between the both groups. However, the strength of our 
study is that we longitudinally followed both the women with MS and the healthy women, 
allowing us to study intra-individual changes in serum leptin levels, irrespective of BMI. 
Furthermore, BMI alone cannot account for the increase of leptin during pregnancy. The 
rise of leptin during pregnancy precedes the increase in BMI and abruptly decreases after 
delivery16,18 because, next to the adipose tissue, the placenta becomes the most important 
source of leptin during pregnancy. 26-27
 Leptin, as discussed before, has important effects on both the innate and adaptive 
immune response. Elevated serum leptin levels cause a proinflammatory immune response. 
The ameliorating effect of the third trimester of pregnancy on disease activity, therefore, 
seems in contrast with the elevated leptin levels during pregnancy. First, it should be noted 
that not all effects of leptin are proinflammatory. In patients with relapsing remitting MS, 
serum leptin enhances the release of the anti-inflammatory cytokine IL-10 in peripheral 
blood mononuclear cells, next to proinflammatory cytokines (IL-6, TNF-α).28-29 Furthermore, 
we observed that SLR is equally increased during pregnancy. The leptin levels, as we 
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measured, represent total leptin levels, including both bound and free leptin. SLR modulates 
leptin activity by competing with the binding to the membrane bound receptor.30 Leptin 
binds to SLR with the same affinity as to its membrane bound receptor in a molar ratio of 
1:1.31 Considering the molecular weight ratio of leptin to SLR (=7.7:1)31, during and around 
pregnancy a constant molar serum leptin to SLR ratio of around 10 is observed (data are 
not shown). The elevated SLR levels could be a counterbalance for leptin availability during 
pregnancy. However, the constant tenfold molar excess of leptin over its soluble receptor 
indicates that the absolute levels of free leptin are still elevated during pregnancy and 
decrease after delivery, despite the change in SLR levels. 
 Notably, we found that women with MS with the largest relative decrease in serum 
leptin levels after delivery more often had a postpartum relapse. It could be hypothesized 
that the increase of leptin in the third trimester has a delayed effect, priming the immune 
system to a more proinflammatory immune response. Supportive of this hypothesis, earlier 
studies show that an increase in serum leptin levels precedes a relapse in humans and the 
clinical signs in EAE32–34, but still future research on this item would be needed. 
 A large relative drop after the delivery could well be a marker for increased risk of a 
postpartum relapse. However in our study, the postpartum visit took place 4–8 weeks after 
delivery, and some of the postpartum relapses would have already taken place. So before 
serum leptin levels can be clinically useful as a marker for postpartum relapse, our result 
have to be affirmed in a new study with additional samples taken within the first week after 
delivery, to make a prediction at a more clinically useful timepoint. 
 We conclude that our data support the hypothesis that leptin is a factor associated 
with MS disease activity. The exact role of leptin in the innate and adaptive immunological 
pathways still remains to be elucidated.35
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abSTraCT
Objective: To identify clinical, radiologic, or CSF factors that predict conversion to multiple 
sclerosis (MS) after a first attack of inflammatory demyelination in children.
Methods: In this nationwide retrospective multicenter study in the Netherlands, 117 children 
below age 16 were included. Fifty-four children presented with a monofocal clinically 
isolated syndrome (CIS) and 63 children with a polyfocal CIS (PCIS).
Results: A second MS-defining attack occurred in 43% of the CIS cases, compared to 21% of 
the patients with PCIS onset (p < 0.006). Basal ganglia and thalamic lesions and lesions larger 
than 2 cm on MRI (considered typical of ADEM) were observed during PCIS, irrespective of 
the presence of encephalopathy. No significant difference in developing MS was found 
in children with PCIS with or without encephalopathy. Elevated IgG index and presence 
of oligoclonal CSF bands were more often observed in children who developed MS. Both 
Barkhof and KIDMUS MRI criteria shared a high specificity and had a high positive predictive 
value for conversion to MS. In children under the age of 10, the Barkhof criteria had a higher 
sensitivity than the KIDMUS criteria, but still lower than in older children.
Conclusions: Barkhof and KIDMUS MRI criteria share a high specificity and positive 
prognostic value for conversion to multiple sclerosis (MS). Sensitivity of these criteria is poor, 
especially in children below 10 years of age. Basal ganglia lesions can occur in patients who 
later develop MS. A substantial number of patients presenting with polyfocal onset and no 
encephalopathy remained monophasic. 
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inTroduCTion
Onset of multiple sclerosis (MS) before the age of 16 years is reported in 2.2–5.0% of the total 
MS population and before the age of 10 years is observed in 0.2– 0.6%.1-5 Diagnosis of MS in 
children can be more difficult than in adults. More frequently than in adults, the first attack 
of inflammation cannot be distinguished from acute disseminated encephalomyelitis 
(ADEM).6-9
Predicting development of MS after a first demyelinating attack is useful because of 
uncertainty of caregivers about prognosis and possible future therapeutic options. A cross-
sectional study in children with MS showed that half of the children with MS fulfilled the 
Barkhof MRI criteria, which are widely accepted as prognostic for developing MS after a first 
clinical attack in adults.10-11 A French study in children with a broad clinical spectrum of 
first demyelinating attacks showed that next to the Barkhof criteria the presence of lesions 
perpendicular to the corpus callosum and only well-defined lesions on MRI (KIDMUS criteria) 
were prognostic for developing MS.8,12 A recent review on MRI abnormalities in children 
with MS stressed the problem of implementing the adult criteria to children and especially 
to the very young, aged under 10 years.13 The aim of this nationwide study was to identify 
clinical, radiologic, or CSF factors predicting development of MS after a first inflammatory 
demyelinating attack in children.
MeThodS
Patients
Patients were identified by members of the Dutch study group on childhood MS and ADEM. 
Eleven major neuropediatric centers in hospitals in nine large cities participated with 
complete geographic covering of the Netherlands. Children under the age of 16 with an 
attack, in the period 1990–2007, compatible with a demyelinating disease of the CNS, based 
on clinical features, were included. No other diagnosis than demyelinating disease of the 
CNS, like bacterial or viral infection of the CNS or a vasculitis, was allowed. Neuromyelitis 
optica (Devic disease) was also excluded. Length of follow-up time was determined by the 
last visit or telephone contact with a neurologist or pediatrician.
Definitions
A clinically isolated syndrome (CIS) was defined as a monofocal attack of CNS demyelination 
(in optic nerve, brainstem, hemisphere, cerebellum, or spinal cord). A polyfocal clinically 
isolated syndrome (PCIS) was defined as a polyregional attack, implicating multiple CNS 
lesions. The term ADEM was avoided because of the incomplete consensus on diagnosis, 
especially considering the diagnostic weight of presentation with encephalopathy and 
findings on MRI, which are studied here as independent variables.14-15 This enabled us 
to dissect patients with PCIS into subgroups with and without encephalopathy at onset, 
without discussion whether they should be labeled as ADEM. Encephalopathy was defined 
as altered consciousness or evident change of behavior at time of debut of the attack (3 
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days before or after the first contact with the treating physician) not related to seizures 
or antiepileptic treatment. We considered a second attack within 1 month after the first 
attack or a second attack while on steroids or a second attack within 1 month after steroid 
discontinuation to be part of the initial first attack. Thus such cases were still labeled as 
monophasic. 
A multiphasic disease course with at least 1 month between two attacks was considered 
MS when there was also dissemination in space, according to the revised McDonald criteria.11
Demographic data.
Demographic, clinical, and laboratory data were collected from chart records by a trained 
researcher using standardized recording sheets and kept in a database. Collected patient 
characteristics were age at onset and gender. Furthermore we scored the presence of a 
preceding infection or vaccination in the 4 weeks before onset, meningism, seizures, fever, 
headache, and the occurrence of a second and third attack.
MRI data
Available scans were done at 1.0 or 1.5 Tesla and typically consisted of transverse T1, T2, 
and proton density 3–5 mm images. In most cases T2-weighted fast-fluid-attenuated 
inversion recovery scans were available. Gadolinium was not administered routinely. 
To avoid reader bias, available MRI scans at baseline were centrally re-evaluated using a 
standardized MRI record form in consensus by two experienced MRI assessors (R.F.N. and 
R.Q.H.), blinded to clinical symptoms, disease evolution, and initial MRI analysis of the 
local neuroradiologist. Lesions were scored on transverse proton density and T2-weighted 
images. Periventricular lesions were defined as lesions in direct contact with the ventricular 
system. Juxtacortical lesions were defined as lesions in direct contact with the cortical gray 
matter with no intervening white matter. Infratentorial locations consisted of brainstem 
and cerebellar lesions. We assessed the fulfillment (at least three out of four) of the Barkhof 
criteria: 1) at least nine lesions on the T2-weighted images; 2) presence of at least three 
periventricular lesions; 3) presence of at least one juxtacortical lesion; 4) presence of at 
least one infratentorial lesion.16 Additional variables tested for prediction of MS conversion 
were white matter lesions perpendicular to the corpus callosum, gray matter lesions in the 
thalamus or basal ganglia, and T2 lesion size (large lesions were defined as lesions with a 
maximal diameter over 2 cm, small lesions had a maximal diameter below 2 cm). We also 
scored the sole presence of well-defined lesions, which were defined by clear lesions borders; 
an abrupt decrease in intensity of T2-weighted signal at the borderline between lesion and 
surrounding brain tissue.12
CSF data
Data on CSF were collected from the period during or soon after the first clinical attack. IgG 
index upper cutoff value of 0.68 was selected.17 CSF oligoclonal bands (OCB) detected with 
immunoelectric focusing were positive in case of two or more bands present in CSF, but not 
in serum.
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Statistical analysis
Descriptive data were compared by means of the χ2 test and Fisher exact test for proportions 
and the t test and Mann-Whitney test for continuous measures. Survival curves were 
estimated using the Kaplan-Meier method. Time zero for the survival analysis was taken as 
the date of the first attack. The primary endpoint was conversion to MS. Time to conversion 
to MS was defined by the time between the first and second attack. For event-free subjects 
the follow-up period ended on the date of the last known visit, at which point the time was 
censored. p Value below 0.05 was considered significant. Statistical analysis was performed 
using SPSS version 11.0.
reSulTS 
A total of 117 children were included in the study with a mean follow-up of 54 months 
(median 43 months, range 5–201 months). Clinical characteristics are depicted in table 1. 
Sixty-five (56%) children had a first presentation below the age of 10 years and 40 (34%) 
below the age of 6. In total, 37 of the 117 patients were diagnosed with MS, fulfilling the 
clinical McDonald criteria. 
PCIS was seen in 63 children. Thirteen of them (21%) had a second MS defining attack. 
The mean time to this second attack was 24.7 months (median: 10 months, range: 2–79 
months). In 5 (38%) children this second attack was again a polyfocal attack. Children with 
PCIS and encephalopathy, fulfilling the proposed international criteria for ADEM,14 had a 
lower age at onset and a higher prevalence of seizures than children with PCIS without 
encephalopathy, but showed no significant difference in the other clinical features. Children 
with PCIS without encephalopathy progressed to MS more frequently then children with 
PCIS with encephalopathy, but this difference was not significant (table 1). Basal ganglia or 
thalamic lesions and large lesions on MRI were both seen in children with PCIS with and 
without encephalopathy (table 1). Using the definitions from the international pediatric 
MS study group,14 we found only two cases of multiphasic ADEM and no cases of recurrent 
ADEM. 
Fifty-four children presented with CIS. Of these 54 children, 12 had optic neuritis, 17 
isolated transverse myelitis, 18 brainstem symptoms, 4 hemispheric symptoms, and 3 had 
cerebellar symptoms. Twenty-four (44%) children with a CIS had a second, MS defining, 
attack. The mean time to conversion to MS after a CIS was 17.7 months (median: 12 months, 
range: 2–75 months). 
Children with a final diagnosis of PCIS were younger, had significantly more often 
encephalopathy, headache, fever, and seizures, as well as a preceding infectious episode 
within the 4 weeks preceding the onset of initial attack (table 2). Mean time to MS diagnosis 
in the total group was 18.6 months (median: 11 months, range: 2–79). This was significantly 
shorter than the duration of follow-up of both the groups with a final diagnosis of CIS (mean: 
52.7 months, median: 42.5 months, range: 12–162 months) and PCIS (mean: 44.8 months, 
median: 32 months, range: 5–201 months). 
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Table 1. Clinical and Mri features at baseline in patients with a diagnosis of CiS and PCiS at 
onset
type of onset
CIS PCIS 
all
with encepha-
lopathy 
no encepha-
lopathy 
p-value* p-value**
clinical features n=54 n=63 n=36 n=27
mean age at onset (years) 10.5 6.8 5.6 8.4 <0.001 0.011
male gender (%) 44 65 72 55 0.025 n.s.
meningism (%) 2 22 31 11 0.001 n.s.
headache (%)  2 32 31 33 <0.001 n.s.
fever (%) 4 38 42 33 <0.001 n.s.
seizures (%)  0 24 36 7 <0.001 0.008
infections (%) 20 49 55 41 0.002 n.s.
vaccination(%) 2 3 6 0 n.s. n.s
cinical outcome at end of follow-up
progression to MS(%) 44 21 17 26 0.006 n.s.
MRI features n=49 n=61 n=35 n=26
thalamus / basal ganglia lesions (%) 4 56 51 62 <0.001 n.s.
large lesions (%) 10 67 80 50 <0.001 0.014
* CIS compared with PCIS (all)
** PCIS with encephalopathy compared to PCIS without encephalopathy 
CIS = clinically isolated syndrome, PCIS = polyfocal clinically isolated syndrome, MS = multiple sclerosis, n.s. 
= not significant
Table 2. Clinical and CSF features and at baseline of children with a final diagnosis of CIS, PCIS 
and MS
final diagnosis at end of follow-up
monophasic
CIS PCIS MS P-value*
clinical data n=30 n=50 n=37
mean age at onset (years)
  range (years)
9.6
1-15
6.4
1-14
10.4
1-15
<0.001
follow up mean (months) 52.7 44.8 66 n.a.
follow up median (months) 42.5 32 60 n.a.
male gender (%) 43 66 51 n.s.
encephalopathy (%) 0 60 16 <0.001
meningism (%) 3 20 11 n.s.
headache (%) 3 34 8 0.005
fever (%) 7 42 8 <0.001
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seizures (%) 0 28 3 0.02
preceding infection (%) 27 50 24 0.015
CSF data P-value**
IgG- index n=17 n=26 n=29
>0.68 (%) 17 27 66 <0.001
oligoclonal banding n=16 n=19 n=26
present (%) 0 16 46 0.001
* MS compared to PCIS
** MS compared to CIS and PCIS
CIS = clinically isolated syndrome, PCIS = polyfocal clinically isolated syndrome, MS = multiple sclerosis, n.a. 
= not applicable, n.s. = not significant
Table 3. Mri features of children with MS and monophasic disease (CiS and PCiS) younger and 
older than ten years at onset of symptoms
MS monophasic disease p-value
all
n=35
<10 yr
n=11
≥10yr
n=24
all
n=75
<10 yr
n=48
≥10 yr
n=27
all <10yr >10yr
Barkhof
≥ 9 lesions T2 (%) 66 64 67 17 21 11 <0.001 0.005 <0.001
infratentorial lesion (%) 88 91 88 43 46 37 <0.001 0.007 <0.001
juxtacortical lesions (%) 74 64 79 31 33 26 <0.001 n.s. <0.001
≥ 3 periventricular lesions (%) 60 55 63 5 4 7 <0.001 <0.001 <0.001
3-4 Barkhof criteria (%) 60 45 67 7 6 7 <0.001 0.008 <0.001
supplemental
lesions perpendicular to 
corpus callosum  (%)
60 27 75 5 6 4 <0.001 0.037 <0.001
thalamus / basal ganglia 
lesions (%)
20 36 13 40 48 26 0.039 n.s. n.s.
large lesions (%) 20 55 4 52 58 41 0.002 n.s. 0.002
small lesions (%) 74 64 79 25 25 26 <0.001 0.013 <0.001
only well-defined lesions (%) 40 36 67 8 6 13 <0.001 0.018 <0.001
KIDMUS (%) 49 18 63 4 4 4 <0.001 n.s. <0.001
CIS = clinically isolated syndrome, PCIS = polyfocal clinically isolated syndrome, MS = multiple sclerosis, 
KIDMUS criteria = presence of both lesions perpendicular to the corpus callosum and only well-defined 
lesions, <10 yr = age at onset under 10 years, ≥10yr = age at onset above 10 years, n.s. = not significant
CSF was obtained in all but one patient. IgG index was tested in 72 children within 1 
month and in one child within 5 months after onset. An elevated IgG index was significantly 
more frequently seen in children with MS. OCB were tested in 61 children within 1 month 
and in two children within 5 months after onset. OCB was significantly more often seen in 
children with MS (table 2). 
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A total of 110 brain MRIs at baseline were available. Five children had only a spinal 
cord MRI and two baseline MRI scans were not available. MRI data are shown in table 3. 
Each of the four individual Barkhof criteria was significantly more often observed with 
children with MS. This was not the case for juxtacortical lesions in children younger than 10 
years. Presence of at least three Barkhof criteria was significantly more frequently found in 
children with diagnosed MS in both age groups. 
Survival analysis of the children scoring at least three Barkhof criteria showed a shorter 
mean time to the second attack of 45 months (95% CI: 18–73) vs 123 months (95% CI: 103–
142) (log-rank test p value < 0.0001) in the other children (figure A). When stratified for age 
below and above 10 years, difference in time to second attack remained significant. 
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figure 1. (A) Survival curves of the time preceding the second attack according to the presence of 0-2 
and 3-4 Barkhof criteria on baseline MRI. Log-rank test p<0.0001. (B) Survival curves of the time preceding 
the second attack according to the presence of both lesions perpendicular to the corpus callosum and the 
presence of only well-defined lesions (KIDMUS criteria) on baseline MRI. Log-rank test p<0.0001. 
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Lesions perpendicular to the corpus callosum and only well-defined lesions (the KIDMUS 
criteria) and small lesions were significantly more often found in children with MS. Large 
lesions and basal ganglia lesions were significantly less frequently observed in children 
with MS. This difference was not seen in children aged under 10. Positivity of both KIDMUS 
criteria was observed significantly more often in children with MS in the total group but not 
in the group younger than 10 years. 
Survival analysis of the children with the KIDMUS criteria showed a shorter mean time 
to the second attack of 22 months (95% CI: 10–33) vs 143 months (95% CI: 119–168) (log-rank 
test p value: < 0.0001) in the children without (figure B). When stratified for age below and 
over 10 years, difference in time to second attack remained significant. The test properties 
of the Barkhof and KIDMUS criteria are described in table 4.
Table 4. Test properties of the barkhof and KidMuS criteria
Barkhof KIDMUS
all <10 years ≥10 years all <10 years ≥10 years
sensitivity (%) 60 45 67 49 18 63
specificity (%) 92 94 93 96 96 96
positive predictive value (%) 81 63 89 83 50 85
negative predictive value (%) 83 88 75 81 84 80
KIDMUS criteria = presence of both lesions perpendicular to the corpus callosum and only well-defined 
lesions, Barkhof criteria = (1) ≥ 9 T2 lesions, (2) infratentorial lesions, (3) juxtacortical lesions, (4) ≥ 3 
periventricular lesions, <10 years = age at onset under 10 years, ≥10years = age at onset above 10 years
diSCuSSion
This nationwide study in the Netherlands focused solely on patients from neuropediatric 
clinics. Due to the retrospective nature of this study, follow-up time of children with a 
monophasic course was shorter than those with MS (table 2). Nevertheless, the time to 
conversion to MS in the MS group was significantly shorter than the duration of follow-
up of the children who remained monophasic. This indicates that follow-up even in the 
monophasic patients was likely sufficient to detect the occurrence of a second attack. It 
is not excluded that children who are now monophasic during follow-up still can have a 
second MS defining attack in the future. 
A diagnosis of ADEM frequently incorporates ADEM- like MRI lesions. These typically 
large lesions are often related to encephalopathy, making it difficult to independently assess 
the contribution of such MRI abnormalities and encephalopathy to further conversion 
into MS. Therefore we avoided the term ADEM, but split the polyfocal onset group into 
subgroups with and without encephalopathy, regardless of MRI findings. The obligatory 
presence of encephalopathy for ADEM diagnosis, as proposed by the international pediatric 
MS study group,14 may carry the risk of underestimation of ADEM cases. In a recent study, 
not all children with a brain MRI typical of ADEM had encephalopathy.8 The definition of 
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encephalopathy deserves further specification in future studies. It has been proposed to 
include in the definition of encephalopathy the presence of irritability and lethargy.14 These 
two features were not part of our definition of encephalopathy, because they may also be 
observed in any generally sick child. 
We also found the presence of large lesions and basal ganglia or thalamic lesions, 
considered typical of ADEM, in children who had a second MS defining attack and even 
in children without encephalopathy. Furthermore, we found no statistical difference in 
progression to MS in the children with PCIS with or without encephalopathy, although there 
was a trend that children with encephalopathy remained more often monophasic. The 21% 
of children developing MS in the whole PCIS group was in line with results reported before.8 
Also time to a third attack during follow-up of children with MS was not related to either CIS 
or PCIS onset type (not shown). An interesting finding was that seizures almost exclusively 
occurred in the group with a monophasic PCIS, which makes seizures a possible relevant 
prognostic factor. Using the definitions from the international pediatric MS study group,14 
we found only two cases of multiphasic ADEM and no cases of recurrent ADEM, indicating 
that these, at least in our study group, constitute a small subgroup of total numbers of 
children with multiphasic demyelinating diseases. 
In adults it is suggested that an elevated CSF IgG index is predictive of MS.18 In children 
this has been studied in less detail. We found elevated IgG indices in the majority of cases 
tested. This sign of intrathecal IgG production was significantly more often found in children 
with MS. OCB in adults is more sensitive and specific than IgG index in the CSF.18 OCB, when 
tested, was found significantly more frequently in the group diagnosed with MS than in the 
group with a final diagnosis of monophasic CIS or PCIS, as has been reported before.19
Three points should be taken into account in respect to the CSF data. First, we did not 
have information on CSF IgG index and OCB in all patients. Second, some samples were not 
taken within 1 month after onset of symptoms, although this only occurred in less than 
5% of the children. Finally, data were collected in multiple laboratories in a period of more 
than 10 years, so OCB were not tested uniformly. However, the main technical variance of 
OCB testing lies in sensitivity. Perhaps future testing in a more optimized and protocolized 
fashion may even improve the predictive power of this test. 
A prognostic factor for progression to MS was the presence of at least three positive 
Barkhof criteria in children aged above and below 10 years at onset. In the French study it 
was observed that lesions perpendicular to the corpus callosum as well as only welldefined 
lesions were prognostic factors for developing MS.10 We confirm this finding, although not 
in the group with age at onset below 10 years. 
Comparison of test qualities of the Barkhof and KIDMUS criteria showed a low sensitivity, 
but high specificity for both sets of criteria. Especially in children below 10 years, sensitivity 
was low. In adults the sensitivity of the Barkhof criteria is 49–74%.16 The low sensitivity of the 
KIDMUS criteria in children under age 10 (18%) has been reported earlier and is confirmed 
here.10 It should be noted that both our and the other available retrospective studies did not 
use standardized MRI protocols. 
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Better tools to predict development of MS are needed. The recent worldwide collaborative 
efforts will provide longer follow-up data on disease course and disability.20 Such studies 
will include the assessment of the possible extra value of scoring dissemination in time 
by MRI, the validation of novel MRI variables, and novel biomarkers. The possibility of a 
subgroup remaining monophasic after presentation with polyfocal CIS, reminiscent of 
ADEM but without encephalopathy, deserves further study.
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abSTraCT
We sought to identify clinical and radiologic features predicting early relapse after a diagnosis 
of multiple sclerosis in children. In this nationwide retrospective multicenter study in The 
Netherlands, we included 28 children with multiple sclerosis with onset before age 16 years. 
Magnetic resonance mages and clinical features at the onset of disease were evaluated. The 
mean follow-up time was 55 months. Twenty children (71%) had a relapse during follow-up.
We found that the presence of at least three of four Barkhof magnetic resonance imaging 
criteria at the onset of multiple sclerosis signs is predictive of early relapse after a diagnosis 
of multiple sclerosis in children (P < 0.05).
Barkhof MRI criteria predict early relapse in pediatric MS
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inTroduCTion
The onset of multiple sclerosis before age 16 years is very rare.1-5 Multiple studies on the 
prognostic value of demographic and clinical features of the course of this disease were 
reported in adult cohorts, not including magnetic resonance imaging data.2-6 Several recent 
studies reported on the prognostic value of multiple clinical features, including magnetic 
resonance imaging and cerebrospinal fluid data, after a first demyelinating attack in 
pediatric cohorts.7-9 These studies shed more light on the sometimes difficult process 
of diagnosing multiple sclerosis in children. Still, little is known about identifying the 
subgroup of children who will undergo early relapse after a diagnosis of multiple sclerosis. 
This knowledge would be useful when counselling children and their parents. Furthermore, 
it would enable us to select children eligible for immunomodulatory treatment in future 
trials. Recently, a childhood-onset multiple sclerosis potential index for early severity was 
proposed.10 This nationwide study sought to identify clinical and radiologic factors predicting 
early relapse after a diagnosis of multiple sclerosis, and to determine the childhood-onset 
multiple sclerosis potential index for early severity in another cohort.
MeThodS
Patients and definitions
Patients were identified by members of the Dutch study group on childhood multiple 
sclerosis and acute disseminated encephalomyelitis. We included children with multiple 
sclerosis who exhibited their first attack before age 16 years, with brain magnetic resonance 
imaging scans available for evaluation, during the period 1990-2007. 
 A multiphasic disease course with at least 1 month between two clinical attacks was 
considered indicative of multiple sclerosis when there was also dissemination in space, 
according to the revised McDonald criteria.11 We considered a second attack within 1 month 
after the first attack, or a second attack during the administration of steroids, or a second 
attack within 1 month after steroid discontinuation, to be part of the initial first attack. 
Thus, such cases were still labeled as monophasic. No diagnosis other than demyelinating 
disease of the central nervous system, such as bacterial or viral infection of the central 
nervous system or a vasculitis, was allowed. Neuromyelitis optica (Devic’s disease) was also 
excluded. The length of follow-up time was determined by the most recent visit or telephone 
contact with a neurologist or pediatrician.
Demographic and clinical data
Demographic and clinical data were collected from chart records by a trained researcher, 
using standardized recording sheets. Patient characteristics included age at onset and 
sex. We also scored the presence of polyfocal onset, encephalopathy, the use of disease-
modifying drugs, the occurrence of a relapse after the diagnosis of multiple sclerosis, and 
time between the first attack and the diagnosis of multiple sclerosis. Encephalopathy was 
defined as altered consciousness or evident change of behaviour at the time of debut of the 
attack, not related to seizures or antiepileptic treatment.
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Magnetic resonance imaging data
All magnetic resonance imaging scans of the brain were evaluated as previously described.7 
We assessed the fulfilment of at least three out of four Barkhof criteria: (1) at least nine 
lesions on the T2-weighted images; (2) the presence of at least three periventricular lesions; 
(3) the presence of at least one juxtacortical lesion; and (4) the presence of at least one 
infratentorial lesion.11 We also scored the presence of lesions in the thalamus and basal 
ganglia. Furthermore, we scored the presence of white-matter lesions perpendicular to the 
corpus callosum and the sole presence of well defined lesions. The last two variables are 
known as the KIDMUS criteria.9
Childhood-onset multiple sclerosis potential index for early severity
The childhood-onset multiple sclerosis potential index for early severity was calculated 
according to the methods of Mikaeloff et al.10 This index is based on the presence of one 
or two of the KIDMUS magnetic resonance imaging criteria, female sex, a short interval 
between the first and second (multiple sclerosis-defining) attack, absence of encephalopathy, 
and a progressive disease course.
Statistical Analysis
Descriptive data were compared by means of the Fisher’s exact test for proportions and the 
Mann Whitney U test for continuous measures. Survival curves were estimated using the 
Kaplan-Meier method. Time zero for the survival analysis was taken as the date of the first 
attack. The primary endpoint was the first relapse after the diagnosis of multiple sclerosis. 
Time to conversion to multiple sclerosis was defined as the time between the first and second 
attacks. For event-free patients, the follow-up period ended on the date of the last known 
visit, at which point the time was censored. We considered P < 0.05 significant. Statistical 
analysis was performed using SPSS, version 16.0 (SPSS, Inc., Chicago, IL).
reSulTS
Twenty-eight children with childhood multiple sclerosis were included. All children 
exhibited relapsing, remitting multiple sclerosis. The mean age at onset was 10.7 years (S.D., 
±3.9 years; median, 12.0 years). Ten (36%) children were less than age 10 years, and four 
(14%) children were aged less than 6 years, at onset. Twenty children (71%) manifested a 
relapse after the diagnosis of multiple sclerosis during follow-up. Three of these 20 children 
underwent interferon-β treatment at that time. The mean time from the diagnosis of 
multiple sclerosis to this relapse was 26 months (range, 2-96 months; median, 16 months). 
The mean follow-up time in the group with no relapse after a diagnosis of multiple sclerosis 
was 51 months (range, 18-95 months; median, 42 months). None of the children exhibited a 
progressive course during follow-up. The clinical and magnetic resonance imaging features 
at time of the first attack are listed in Table 1. The presence of three or more periventricular 
lesions, lesions perpendicular to the corpus callosum, and at least three of four Barkhof 
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magnetic resonance imaging criteria were associated with a relapse during follow-up. 
Moreover, the absence of polyfocal onset with encephalopathy, and the absence of thalamic 
and basal-ganglia lesions, were associated with relapse during follow-up. 
Table 1. Clinical and MRI features at time of the first attack
relapse after diagnosis MS
all
n=28
present
n=20
absent
n=8
p-value
clinical features at first attack
age at onset MS >10 years 19 15 4 n.s.
female gender 14 11 3 n.s.
time between first attack and 
diagnosis MS <12 months 
15 13 2 n.s.
PCIS with encephalopathy 5 1 4 0.015
PCIS 9 4 5 n.s.
MRI features at first attack
≥9 lesions on T2 21 17 4 n.s.
infratentorial lesions 25 19 6 n.s.
juxtacortical lesions 21 16 5 n.s.
≥3 periventricular lesions 17 15 2 0.030
thalamic / basal ganglia lesions 6 2 4 0.038
lesions perpendicular to corpus callosum 16 14 2 0.044
only well defined lesions 17 13 4 n.s.
3 or 4 Barkhof criteria 18 16 2 0.011
1 or 2 KIDMUS criteria 21 15 6 n.s.
2 KIDMUS criteria 15 13 2 n.s.
MS = multiple sclerosis, PCIS = polyfocal clinically isolated syndrome, 
Barkhof criteria: 1) at least nine lesions on the T2-weighted images; 2) presence of at least three periventricular 
lesions; 3) presence of at least one juxtacortical lesion; 4) presence of at least one infratentorial lesion
KIDMUS criteria: 1) white matter lesions perpendicular to the corpus callosum; 2) only well defined lesions
 The mean childhood-onset multiple sclerosis potential index for early severity was 7.4 
(S.D. ±3.1) in the group with relapse after follow-up, and this index was lower in the group 
without relapse, at 4.9 (S.D. ±3.8). This difference was not statistically significant. 
 A survival analysis of the children meeting at least three Barkhof criteria indicated a 
shorter mean time to first relapse of 31 months after a diagnosis of multiple sclerosis (95% 
confidence interval, 16-45 months), versus 62 months (95% confidence interval, 39-84 
months) (log-rank test P value, 0.049) in the other children (Fig 1).
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figure 1. Survival curves of the time preceding the next relapse after diagnosis MS according to the 
presence of 0-2 and 3-4 Barkhof criteria on baseline MRI (Log-rank test p=0.049). (Barkhof MRI criteria: 
1. at least nine lesions on the T2-weighted images; 2. presence of at least three periventricular lesions; 3. 
presence of at least one juxtacortical lesion; 4. presence of at least one infratentorial lesion)
diSCuSSion
In this nationwide multicenter study, we evaluated several clinical and radiologic parameters 
in children with a diagnosis of multiple sclerosis. Using survival analysis, we found that the 
presence of at least three positive Barkhof criteria in children was a prognostic factor for 
early relapse after a diagnosis of multiple sclerosis. 
 The retrospective nature of our study and the relatively small number of patients limited 
our analysis. The minimal follow-up time in the group with no relapse after the diagnosis 
of multiple sclerosis was 18 months. Naturally, the children with no relapse may exhibit 
relapse in the future. 
 We know of only one other study to report on prognostic factors for early relapse in 
a pediatric cohort .10 This French study, investigating prognostic factors for early severity 
in children with multiple sclerosis, indicated that the presence of one or two of the 
KIDMUS magnetic resonance imaging criteria, female sex, a short interval between the 
first and second (multiple sclerosis-defining) attacks, the absence of encephalopathy, and a 
progressive course of disease were independent prognostic factors for early severity. Except 
in terms of progressive course of the disease, we observed the same trend for all of these 
features, but these differences did not achieve statistical significance. The childhood-onset 
multiple sclerosis potential index for early severity was higher in children who manifested a 
relapse after the diagnosis of multiple sclerosis, although this difference was not significant. 
 A difference between our study and this French study was that their endpoint definition 
was the occurrence of a relapse after the diagnosis of multiple sclerosis or development of an 
expanded disability status score12 of 4.Nevertheless, a majority (>95%) of those children who 
reached the endpoint manifested a relapse after the diagnosis of multiple sclerosis before 
ever developing an expanded disability status score of 4, making our study comparable with 
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the French study. 
 We agree with the French study on the importance of using magnetic resonance imaging 
criteria, to identify those children with a high risk of early relapse. Still larger collaborative 
prospective studies are required to address this question fully. These efforts should also 
include an international consensus on the definition of disease severity.
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Background: Brain MRI is a useful tool for diagnosing inflammatory demyelinating 
disorders in children. However, it remains unclear which are the most reliable criteria 
for distinguishing multiple sclerosis (MS) from monophasic disorders such as acute 
disseminated encephalomyelitis (ADEM). We therefore compared the 4 current sets of MRI 
criteria in our Dutch pediatric cohort and determined which are the most useful in clinical 
practice for distinguishing ADEM from MS.
Methods: We included 49 children who had had a demyelinating event and an MRI scan 
within 2 months of their first clinical attack. Twenty-one patients had ADEM and remained 
relapse-free after at least 2 years of follow-up. Twenty-eight patients had a definitive 
diagnosis of MS. We assessed the sensitivity and specificity of the following MRI criteria: 
Barkhof criteria, KIDMUS criteria, Callen MS-ADEM criteria, and Callen diagnostic MS 
criteria.
Results: The Callen MS-ADEM criteria had the best combination of sensitivity (75%) and 
specificity (95%). The KIDMUS criteria had higher specificity (100%), but much lower 
sensitivity (11%). The Barkhof criteria had a sensitivity of 61% and a specificity of 91%. The 
Callen diagnostic MS criteria were the most sensitive (82%), but were only 52% specific for 
distinguishing a first attack of MS from ADEM.
Conclusions: The results in our cohort demonstrate that the new Callen criteria for multiple 
sclerosis-acute disseminated encephalomyelitis (MS-ADEM) are the most useful for 
differentiating a first attack of MS from monophasic ADEM. Although the Callen diagnostic 
MS criteria are more sensitive, they lack the specificity necessary to differentiate MS from 
ADEM.
A comparison of MRI criteria for diagnosing paediatric ADEM and MS
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inTroduCTion
In children who have a first attack of immune-mediated demyelination, it is usually difficult 
to distinguish multiple sclerosis (MS) from acute disseminated encephalomyelitis (ADEM). 
This distinction is important, because ADEM is considered a monophasic disease with a more 
benign course, while MS is a lifelong chronic illness. Multiple subsequent attacks leading to 
a diagnosis of MS occur in approximately 20% of children initially diagnosed with ADEM.1-5 
MRI is a useful tool in confirming the diagnosis of acute immune-mediated demyelination 
and may become more useful for recognizing patients who are at risk of future attacks of 
demyelination or MS. Until recently, 2 sets of criteria were available for predicting conversion 
to MS after a first demyelinating event: the Barkhof MRI criteria were developed for adult 
patients6 and the MRI KIDMUS criteria were the first criteria developed for children.7 In our 
Dutch cohort of pediatric MS patients, we have already confirmed that both sets of criteria 
have a high specificity and positive predictive value.4 However, their sensitivity is poor, 
especially in children younger than 10 years.4-5,7-8 
Two recent studies by one group emphasize the need to develop MRI criteria in children 
that can reliably distinguish the first attack of MS from ADEM and other neurologic 
diseases.8-9 The first study developed criteria that can help distinguish patients with MS at 
first attack from patients with monophasic ADEM.8 The second study proposed modifications 
to the Barkhof criteria that would enhance the diagnostic accuracy of these criteria for MS 
in children. These criteria were initially designed to distinguish between MS (at second 
attack) and other, nondemyelinating, diseases (SLE and migraine). As the authors state, it is 
necessary to evaluate the usefulness of these criteria in predicting conversion to MS at the 
first demyelinating attack.9 
Although all these criteria were developed for a slightly different purpose, it is of interest 
to assess to what extent these criteria are useful to distinguish MS at first attack from 
monophasic ADEM, and in that way can predict conversion to MS. Therefore we compared 
the test properties of the existing MRI criteria for MS in distinguishing MS at first attack 
from ADEM and validated the recently proposed criteria in our Dutch pediatric cohort.
MeThodS
Patients and definitions
We included consecutive patients under 17 years old whose first demyelinating event of 
the CNS had occurred between 1995 and 2008. All children were identified by the Dutch 
Study Group for Pediatric MS, which consists of 15 major pediatric neurology centers in the 
Netherlands. Uniform definitions were used across sites. Clinical data were retrieved from 
a central database.4 
Children were only eligible for this study when a cerebral MRI scan had been obtained 
within 2 months of the first clinical event and when a follow-up time of at least 2 years 
was reached. We classified children as either monophasic ADEM or MS (based on clinical 
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features).10 The only difference with the International Pediatric MS Study Group consensus 
definition for monophasic ADEM outcome10 was that we did not strictly require the presence 
of encephalopathy at onset. In all MS cases the diagnosis was based on the clinical course 
(exacerbations), and not solely on new MRI activity. All MS cases in this study had more 
than 2 additional exacerbations after the initial clinical attack. We excluded patients with 
multiphasic or recurrent variants of ADEM as well as patients with neuromyelitis optica.10
Standard protocol approvals, registrations, and patient consents
This study was approved by the Medical Ethical Committees of the Erasmus University 
Medical Center in Rotterdam and of the other participating centers. Written informed 
consent was obtained from all patients or their parents.
MRI analysis
All MRI scans were performed on a 1.5-TeslaMRI scanner with slice thicknesses of 3–5 
mm. The lesions was determined on T2-weighted and fluid-attenuated inversion recovery 
sequences. T1-weighted images were used to determine the presence of black holes. All 
scans were scored blinded to diagnosis by 2 experienced raters (I.A.K. and R.F.N.). All lesions 
were located and measured in accordance with the technique described previously.9 We 
defined small lesions as being less than 2 centimeters in diameter in the axial dimension, 
and large lesions as having a maximum diameter of more than 2 centimeters. 
MRI scans were classified as meeting the published Barkhof,6 KIDMUS,7 or Callen criteria 
(see table 2).8-9
Statistical analysis
We counted the total number of patients in the MS group and in the ADEM group who 
fulfilled the 4 sets of MRI criteria. Subsequently we calculated the sensitivity, specificity, 
positive predictive value, and negative predictive value of the different sets of criteria. 
We also assessed the interrater reliability (Cohen κ). Analyses were performed using SPSS 
version 14.0.
reSulTS
Twenty-eight patients with MS and 21 patients with ADEM met our inclusion criteria 
(figure). Their clinical characteristics are shown in table 1. All patients in the ADEM group 
were polysymptomatic at presentation. Encephalopathy occurred more frequently in the 
ADEM group (52% vs 7% in the MS group). All patients with MS experienced subsequent 
clinical attacks. Two of the patients with MS had an initial demyelinating event consistent 
with the diagnosis of ADEM (with encephalopathy), but later went on to have multiple 
relapses typical for MS and demonstrated new lesion accrual on MRI. 
Table 2 shows the test properties of the 4 sets of MRI criteria. The application of the 
newly proposed Callen MS-ADEM criteria had the best sensitivity (75%) and specificity 
A comparison of MRI criteria for diagnosing paediatric ADEM and MS
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(95%) for distinguishing MS at first attack from ADEM. Their proposed diagnostic MS criteria 
were 82% sensitive and 52% specific (table 2). 
The Cohen κ value for interrater reliability was 0.84 for the MS-ADEM criteria and 1.0 for 
the other criteria.
Table 1. Patient characteristics
MS patients
N=28
ADEM patients
N=21
female / male 14 / 14 5 / 16
age at onset disease, y, mean ± SD 12.41 ± 3.8 6.76 ± 4.3
follow-up time, y, mean ± SD 3.6 ± 2.9 3.8 ± 2.6
clinical presentation at first attack:
monofocal 13 (46%) 0  (0%)
polyfocal without encephalopathy 13 (46%) 10 (48%)
polyfocal with encephalopathy 2  (7%) 11 (52%)
ADEM = acute disseminated encephalomyelitis; MS = multiple sclerosis.
Figure 1. STARD flow diagram
ADEM = acute disseminated encephalomyelitis; MS = multiple sclerosis. 
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diSCuSSion
In our cohort, we confirmed the high sensitivity and specificity of the newly proposed Callen 
MS-ADEM criteria.8 The sensitivity of these criteria in distinguishing between ADEM and 
MS after a first demyelinating event in children is higher than of the previous available 
Barkhof and KIDMUS MRI criteria. 
Unlike the original study, we did not require the presence of encephalopathy for the 
clinical diagnosis of ADEM in the present study. It has previously been shown that ADEM-
like disease also exists without encephalopathy.1,4 Children with a polysymptomatic disease 
with encephalopathy are likely to have different MRI lesion characteristics, including larger 
and more diffuse bilateral cerebral lesions, than children without encephalopathy. Since 
“the absence of a diffuse bilateral lesion pattern” is included in the criteria to distinguish 
MS at first attack from ADEM,8 we wanted to investigate whether these criteria were still 
applicable in children with monophasic polyfocal disease without encephalopathy at 
onset. It is interesting that irrespective of monophasic polyfocal disease with or without 
encephalopathy, the specificity of these criteria remained the same when applied to our 
pediatric population. 
In addition to this, we reclassified our groups according to the international consensus 
definition for ADEM, thus excluding patients without encephalopathy at onset. This did not 
significantly change the sensitivity and specificity of the criteria (data not shown). 
We found a perfect interrater reliability. This is notable because “diffuse bilateral lesions” 
remains a subjective criterion, lacking a precise definition in the literature.8 
Large lesions are more frequently seen in children with a monophasic disease than in 
children with MS, but this difference is only observed after the age of 10 years.4 We would 
therefore recommend studying these criteria in 2 larger groups of children: 1 group below 
10 years old and 1 group above this age. 
We confirmed that the newly proposed Callen diagnostic MS criteria have a high 
sensitivity, but the lowest specificity when used to distinguish between ADEM and MS at 
first attack.8 In their original study, these criteria were designed to distinguish between MS 
at the time of second attack and other, nondemyelinating, diseases.9 However, at the initial 
presentation, the MRI distinction between a first attack of MS and other demyelinating 
disease such as ADEM is usually more difficult, which may explain the lower sensitivity and 
specificity when applied at the time of first attack. 
Of all criteria currently available, the Callen MS-ADEM criteria appear to be the most 
useful in clinical practice for children with a first demyelinating event, specifically for 
distinguishing between children with a monophasic polysymptomatic demyelinating event 
(ADEM) and those who are at risk of developing a second demyelinating attack and thus of 
converting to MS. Still, these findings need to be interpreted with caution because of the 
limited sample size in our study and in previous studies. Furthermore, although the length 
of follow-up time is comparable in both groups, the time in the ADEM group is still relatively 
short to state with complete certainty that they will remain monophasic in the future. It 
will be important to examine whether these criteria reliably predict future conversion to 
MS in a prospective cohort of children with a first attack of demyelination. Multinational 
collaborations would significantly help this endeavor.
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SPeCial SiTuaTionS in MS
Through study of natural disease course and natural modifiers, important lessons can be 
learned about etiology, pathogenesis, prognosis and perhaps ultimately new treatment 
options in multiple sclerosis (MS). This thesis focusses on two special and different situations 
in MS: pregnancy and MS and childhood onset of MS. Our studies on MS pregnancy had 
several aims. We wanted to asses clinical disease course of MS around pregnancy and study 
possible predictors of postpartum relapse We also aimed to investigate possible underlying 
biological mechanisms of disease amelioration during pregnancy. The aim of our studies 
on childhood onset of MS was to improve the diagnosis of MS in children. We also set out 
to identify parameters to identify children with MS developing an early relapse after the 
diagnosis of MS. 
In this chapter, the findings and lessons learned from our studies will be summarized 
and discussed. Recommendations for future research will be addressed.
 
i. PreGnanCy in MulTiPle SCleroSiS: SoMe anSWerS, buT alSo neW 
queSTionS
What did we learn from the clinical studies on MS during pregnancy
In this part the main findings and conclusions of the clinical studies on pregnancy and MS, 
described in chapter 2.1, 2.2 and 2.3, will be discussed.
Clinical course of MS during and after pregnancy
In chapter 2.1 we describe the clinical course of multiple sclerosis before, during and 
after pregnancy.1 The strength of our study was that we not only studied relapse rate, but 
also clinical MS scales: the expanded disability status scale (EDSS), the Guy’s neurological 
disability scale (GNDS), the multiple sclerosis impact scale 29 (MSIS-29), an MS self-report 
scale, and a scale addressing health related quality of life (QoL): the MOS 36 item short 
form health survey questionnaire (SF-36). We found that the relapse rate increased in the 
first three months after delivery, yet normalized within one year after delivery, thereby 
confirming previous studies.2-4 Health-related QoL was improved during pregnancy, most 
appreciated in the SF-36 domains vitality and general health. A year after delivery we found 
no adverse effects on MS disease activity at group level, measured by the EDSS, MSIS-29, and 
the GNDS. A year after delivery QoL, measured by the SF-36, was not unfavorably altered 
when compared with QoL during pregnancy. This indicates that, although the number 
of relapses is increased in the short term after delivery, there are no adverse effects of 
pregnancy on disease course in the mid-long term after delivery. These results will help 
neurologists and MS nurses in counseling women with MS who want to become pregnant.
Predicting postpartum relapse
MS relapses are never welcome, but certainly not during the first three months after delivery. 
Predicting such a post-partum relapse would be most helpful. One important implication of 
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identifying women with a high risk for a postpartum relapse is that those women would be 
eligible for possible prophylactic treatment (i.e. corticosteroids).
Until now the only known predictors of a postpartum relapse, identified by the French 
Pregnancy in MS (PRIMS) study, were: number of relapses in the year preceding pregnancy, 
number of relapses during pregnancy, and duration of disease.3 We were not able to 
reproduce these results (chapter 2.1). Most likely, the relative small number of patients in 
our cohort limited our conclusions.
Recently, breastfeeding was shown to have a protective effect on disease activity after 
delivery.5 We and others did not confirm this finding (chapter 2.2).2-4,6-8 
We did find that high serum level of the chemokine interleukin-8 (IL-8) during the 
first trimester was associated with a high chance of postpartum relapse (chapter 2.3).9 
Although the low positive predictive value will likely limit clinical use of IL-8 as a predictor 
of postpartum relapse, this study is the first to shed light on possible biomarkers predicting 
postpartum relapse. Confirmation of our finding in another cohort is required before IL-8 
can be used in clinical practise.
What did we learn from the immunological studies in MS pregnancy
The main findings and conclusions of the immunological studies, described in chapter 
2.4, 2.5 and 2.6, will be discussed in the following part. At the start of our studies we 
hypothesized that during pregnancy in MS patients the adaptive arm of the immune system 
is skewed from pro-inflammatory to anti-inflammatory. Compensating for this decrease in 
pro-inflammatory adaptive immune function, we expected the innate arm of the immune 
system to be more activated. 
Innate immunity: increased monocyte activation during MS pregnancy
In chapter 2.4 we chose to perform a genome wide approach on alterations of the 
transcriptome of monocytes of MS patients before and during the third trimester of 
pregnancy.10 We hoped to identify activation or depression of immunological pathways in 
monocytes that might explain the amelioration of MS during pregnancy. We found that 
during pregnancy expression of the Fc receptor CD64 was increased. This was in line with 
previous studies in healthy pregnant women.11-14 CD64 belongs to the family of receptors for 
the Fc portion of immunoglobulins, and is the high affinity receptor for the Fc fragment of 
IgG.15 It binds best to IgG3 and IgG1, followed by, with decreasing efficacy, IgG4 and IgG2.15 
Ligation of the Fc fragment of IgG to CD64 results in phagocytosis, respiratory burst and 
secretion of pro-inflammatory cytokines.16 Monocyte activation, such as found in sepsis, is 
associated with high CD64 expression.17 In another autoimmune disease, systemic lupus 
erythematosus nephritis, increased expression of CD64 on monocytes is correlated with 
systemic inflammation.18 Our results therefore support our hypothesis that the innate arm 
of the immune system is more activated during pregnancy, 
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Adaptive immunity: frequencies of circulating regulatory T cells (Treg) and T helper (Th)17 
cells
In chapter 2.5 we studied both Treg and Th17 cells as both subsets are implicated in both 
pregnancy homeostasis and MS pathology.19 
We first focused on the anti-inflammatory Treg. Previous reports showed conflicting 
results in healthy women.20-26 This was also the case in the few available studies on Treg 
frequency in peripheral blood in MS during pregnancy.27-29 A major problem interpreting 
these studies in both healthy women and MS patients was the methodological diversity. 
Different gating strategies identifying Treg and the absence of a pre-pregnancy baseline 
sample or postpartum sample hindered comparison of these studies. Another issue was that 
some studies sampled at random moments during pregnancy, instead of sampling at a fixed 
moment. Therefore we performed a longitudinal study including a baseline pre-pregnancy 
sample and two samples after delivery, in addition to two samples during pregnancy in a 
fixed schedule. 
Unexpectedly, we found that the numbers of circulating Treg were decreased, and 
not increased, during the first and third trimester of pregnancy. A possible explanation 
of this decline in circulating Treg could be that circulating Treg are recruited to the fetus 
implantation site from the peripheral maternal blood.25 Intriguingly, treatment with anti-
CD25 antibodies (daclizumab) was also characterized by decreased numbers of Treg in 
peripheral blood in MS patients, comparable with the situation during pregnancy. This was 
not negatively correlated with the reduction in the observed MRI disease activity during 
treatment with daclizumab.30 This indicates that sustained suppressed numbers of Treg in 
peripheral blood do not necessarily negatively influence MS.
As a next step we focussed on Th17 cells. Th17 cells have been implicated in blood brain 
barrier disruption and brain inflammation in MS pathology.31-33 Frequencies of Th17 cells 
during pregnancy have not been studied extensively. One study showed no differences 
during pregnancy34 while another study found decreased numbers of Th17 cells during 
pregnancy.26 We found no differences in the frequencies of circulating Th17 cells during 
pregnancy in MS patients and healthy controls.
Taken together our results do not support the hypothesis that peripheral blood Th17 
cells and Treg are directly involved in MS disease course alteration during pregnancy.
Leptin: a bridge between endocrinology and immunology?
In chapter 2.6 we studied serum levels of leptin before, during and after pregnancy in MS 
patients and healthy controls.35 Leptin was first identified as an adipocyte derived modulator 
of energy homeostasis. Leptin also has major effects on both innate and adaptive immune 
responses, shifting both the innate and adaptive arm of the immune system to a more pro-
inflammatory response.36-39 
We observed a significant increase in serum levels of leptin in women with MS during 
the third trimester, compared to baseline and first trimester samples35 as was observed 
before in healthy women.40-42 Serum levels of leptin during pregnancy were not associated 
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with a postpartum relapse. Therefore serum levels of leptin during pregnancy cannot be 
used as a biomarker for postpartum relapse. 
Notably, we found that women with MS with the largest relative decrease in serum 
leptin levels after delivery more often had a postpartum relapse. Perhaps the increase of 
leptin in the third trimester is part of a process, priming the immune system to a more pro-
inflammatory immune response. Supportive of this hypothesis is that previous studies show 
that an increase in serum leptin levels precedes a relapse in humans and the clinical signs in 
experimental autoimmune encephalomyelitis (EAE).43-45 The priming of the immune system 
during pregnancy to a more pro-inflammatory response was also suggested by a recent 
study that found that a decline in CD4+ IFN-γ producing cells during the end of pregnancy 
was associated with postpartum relapse in MS patients.46 
Future perspective on remaining questions in MS pregnancy
The regulation of immune tolerance and reactivity during pregnancy is highly complex. Our 
data was not supportive for a role of circulating Treg and Th17 cells in disease ameliorating 
during pregnancy in MS. As hypothesized we found evidence of increased activation of the 
innate arm of the immune system. A logical next step is to further explore innate immunity 
during pregnancy in MS. As Natural Killer (NK) cells are abundant at the implantation site 
this cell type is a likely candidate for further research (figure 1).47 
It may also be possible that amelioration of MS during pregnancy is not related to 
immune cell populations in the peripheral maternal blood. Adding pregnancy serum to T 
cell cultures suppresses T cell proliferation in EAE.48 It can be hypothesized that pregnancy 
related serum factors, possibly derived from the fetal/placental compartment, migrate to 
the maternal peripheral blood compartment. These serum factors may exert effects on 
the immune system, eventually influencing disease activity in the brain. These putative 
pregnancy related serum factors are a target for future research. Several candidates will be 
discussed below. It is possible that these pregnancy related serum factors can also be used 
as biomarkers to predict postpartum relapse. 
The following part of the discussion will first discuss possible other innate immune 
functions that may influence pregnancy induced disease ameliorations, focussing on NK 
cells. Hereafter possible serum pregnancy factors will be discussed. Finally, possible candidate 
biomarkers for postpartum relapse and potential treatment options for postpartum relapse 
will be discussed.
Focussing on the innate immunity (dark gray circles) we found, as hypothesized, evidence 
of increased activation of monocytes. Other innate immune cells present in the decidua 
are uterine natural killer cells (uNK). These uNK cells play an important role in pregnancy 
maintenance. NK cells are also present in peripheral blood. NK cells are divided into two distinct 
types based on their expression of CD16 and CD56. CD16-CD56bright (marked CD56+ in figure) 
cells are poorly cytotoxic, whereas CD16+CD56dim (marked CD56- in figure) cells are highly 
cytotoxic but poor at cytokine production. CD16-CD56bright cells increase during pregnancy and 
CD16+CD56dim cells decrease during pregnancy in the maternal peripheral blood. 
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figure 1. immune regulation during MS pregnancy: a summary of our results and adding some 
putative mechanisms
Focussing on the adaptive immunity (light gray circles), we found that the numbers of circulating Treg 
decreased in the peripheral blood whereas the number of circulating Th17 cells remained the same. The 
decrease in circulating Treg can possibly be explained by entry of Treg from the peripheral blood into the 
decidua. It is unknown if Th17 cells enter the decidua from the maternal peripheral blood.
Next to immune cell populations in the peripheral blood, it is also possible that certain 
pregnancy related serum factors exert effects on the immune system, eventually influencing 
disease activity in the brain. Possible serum factors include: cytokines/chemokines (i.e. 
interleukin(IL)-4, IL-10, IL-8, IL-17, IFN-γ), hormonal factors (i.e.: leptin, cortisol, vitamin D, 
estrogens, prolactin), or other factors (micro RNA, soluble HLA-G (sHLA-G), Galectin-1 (Gal-1), 
pregnancy related immune suppressive exosomes).
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Further study of innate immunity: NK cells
NK cells are not only effector cells of the innate arm of the immune system. NK cells are also 
able to modify outcome of adaptive immune responses.49 The NK cell response is based on 
the several NK subsets and biased to either cytokine expression or cytotoxicity. In humans 
NK cells are divided into two major subtypes based on their differentiated ability for 
cytokine expression and cytotoxic capacity. CD16+CD56dim NK cells constitute around 90% 
of the NK cells in peripheral blood and are highly cytotoxic. Most NK cells in lymph nodes 
are CD16-CD56bright and poorly cytotoxic, but readily produce cytokines.50-51
Uterine NK cells represent a special subset of NK cells.52 These cells are CD16-CD56bright 
and produce pro-angiogenic factors like vascular endothelial growth factor (VEGF).53 These 
cells are supposed to play an important role in trophoblast invasion and remodelling of 
decidual arteries. Uterine NK cell function is highly dependent on environmental changes.51 
One of the protective mechanisms of NK cells in pregnancy is secretion of Galectin 1 (Gal-
1). Gal-1 expression is increased in uterine NK cells.52 Gal-1 modulates T cell homeostasis 
by interfering with T cell activation, promoting T cell apoptosis, T cell migration and 
regulating the Th1/Th2 cytokine balance towards Th2 predominance.51,54-55 Uterine NK cells 
interact with HLA-C molecules using killer immunoglobulin like receptors (KIR). This KIR 
can be activating (KIR2DS) or inhibiting (KIR2DL). The HLA-C ligands for KIR on trophoblast 
cells can belong to two groups, HLA-C1 and HLA-C2. This maternal–fetal immunological 
interaction therefore involves two polymorphic gene systems, maternal KIRs and fetal 
HLA-C molecules. NK-cell function is therefore likely to vary in each pregnancy. Some KIR/
HLA-C combinations might be more favourable to trophoblast-cell invasion than other 
combinations.
Interestingly, treatment in MS patients with daclizumab or IFN-β is associated with 
an increase in circulating CD56bright NK cells.56-57 Expansion of CD56bright NK cells during 
treatment with daclizumab is positively correlated with the contraction of the number of 
CD4+ and CD8+ T cells. In vitro these NK cells are able to inhibit T cell survival. In EAE, mice 
deprived of NK cells, showed earlier disease and more severe disease than controls.58
During pregnancy an increase in CD56bright NK cells and decrease in CD56dim NK cells 
is observed in the peripheral blood of MS patients.29 Unfortunately, no sample before 
pregnancy was available in this study. Currently no data on cytokine or Gal-1 profile of these 
CD56bright NK cells during pregnancy in MS patients are available. 
In conclusion, NK cells play an important regulatory role in successful pregnancy. 
Exploring these subsets of NK cells and their cytokine expression or cytotoxic capacity 
during pregnancy in MS patients is therefore a logical next step. In the ideal situation both 
placental tissue and samples of peripheral blood would be available for studying both 
uterine and peripheral blood populations of NK cells.
Pregnancy related serum factors
In the next part I will discuss possible pregnancy related serum factors, likely to have an 
influence on MS disease activity during and after pregnancy.
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Estrogens
Serum levels of estrogens increase during pregnancy. The three main increased estrogens 
in pregnancy are: estrone, 17-β estradiol and estriol. In the early phase of pregnancy these 
estrogens are produced by the ovaries. In the later phase of pregnancy the placenta becomes 
the major supplier of estrogens. In late pregnancy the most abundant estrogen is estriol. 
Estriol treatment in relapsing remitting MS patients positively influences MRI disease 
activity59 and causes an anti-inflammatory Th2 immune respons.60 In EAE mice treated with 
estrogens disease severity is also reduced.61-63 In these estrogen treated mice IL-10 production 
is increased.61 It can be hypothesized that changes in the concentration of estrogens during 
and after pregnancy may be linked to altered disease activity.
Prolactin
Inhibition of prolactin production by bromocriptin reduces severity of EAE.64-65 During 
relapses in MS patients an increase in prolactin is observed.66-67 These findings indicate that 
prolactin may negatively influence disease activity in MS. Alternatively, breast-feeding, a 
situation with increased levels of prolactin, is implicated to protect against postpartum 
relapse5, although not confirmed by us.6 No studies on prolactin levels during and after MS 
pregnancy have been performed yet. 
Cortisol
Pregnancy induced hypercortisolism may be related to decreased disease activity during 
pregnancy whereas the relative drop in cortisol after delivery may be related to the increased 
risk of a postpartum relapse. Serum cortisol levels have not been evaluated in MS pregnancy.
Vitamin D
In general, incidence of MS increases as the distance from the equator increases.68 This has led 
to the hypothesis that exposure to sunlight and vitamin D are involved in MS pathogenesis 
and that appropriate levels may protect against MS.69 Serum vitamin D levels in MS patients 
during and after pregnancy have been explored.70 Vitamin D serum levels after delivery are 
lower in the patients that exclusively breastfed their children compared to patients that did 
not. Surprisingly, this study found that high serum levels of vitamin D after delivery are 
associated with a postpartum relapse. Confirmation of these is results is necessary, because 
this study had some methodological limitations like the lack of a baseline sample before 
pregnancy and lack of healthy controls. 
Cytokines
Our data are not supportive for a role of peripheral blood Treg and Th17 cells in disease 
amelioration during pregnancy in MS. A possible explanation for the decrease in circulating 
Treg in the peripheral maternal blood, is that they enter the decidua25 to locally exert 
regulatory effects and to favour a local anti-inflammatory response. This local decidual 
immune response could cause an increase in serum levels of anti-inflammatory cytokines 
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like IL-4 an IL-10, whereas serum levels of pro-inflammatory cytokines like IFN-γ and the 
Th17 cell product IL-17 could decrease. It can be postulated that these changes in serum 
concentrations of pro-inflammatory and anti-inflammatory cytokines regulate not only 
local decidual immune function, but also systemic immune function, eventually affecting 
disease activity in the brain.
Soluble human leucocyte antigen (HLA)-G
Expression of non-classical major histocompatibility complex (MHC) class I molecule HLA-G 
by trophoblast cells is one of the several mechanisms for limiting T cell awareness of the 
semi-allogenic foetus.71 In MS patients high levels of soluble HLA-G in serum and CSF are 
associated with a reduced lesion burden on MRI, suggesting that high soluble HLA-G levels 
ameliorate MS.72-73 Low serum levels of soluble HLA-G during pregnancy in MS patients are 
associated with an increased risk of a postpartum relapse.74 The possible predictive value of 
low serum levels of soluble HLA-G as a biomarker has yet to be studied.
Pregnancy related micro RNA (miRNA)
MiRNA are 20-24 nucleotides long and are derived from longer RNA precursors. MiRNA 
bind to messenger RNA (mRNA), leading to inhibition of translation, or mRNA degradation. 
Analysis of white matter tissue lesions and blood from patients with MS showed that the 
presence of a specific miRNA, i.e. miRNA-326 is strongly upregulated in active lesions and in 
peripheral blood cells in MS patients and promotes Th17 cell differentiation.75-76
 In pregnancy, placental expression of several miRNA is increased and likely plays an 
important role in implantation and pregnancy.77 During pregnancy these miRNA are also 
detectable in serum and after delivery they disappear.78-79 It can be hypothesized that, 
specific pregnancy related, miRNA expression are associated with amelioration of MS 
during pregnancy.
Immunosuppressive exosomes in pregnancy serum
Recently, it was found that administration of pregnancy-derived serum exosomes to mice 
with established EAE reduced clinical severity.80 These exosomes, containing cytosol and 
exposing extracellular domains of membrane bound proteins, are able to suppress activation 
T cells in vitro. They suppress activation of myelin-specific T cells, as was measured by a 
reduction in proliferation and IFN-γ production.81 The role of these immunosuppressive 
exosomes in during pregnancy in MS patients has not been investigated yet. 
Serum levels of Gal-1
Gal-1 has strong immunomodulatory effects. Gal-1 can modulate T cell homeostasis by 
interfering with T cell activation, promoting T cell apoptosis, T cell migration and regulating 
Th1/Th2 cytokine balance towards Th2 predominance.51,54-55 During pregnancy Gal-1 
expression is increased in uterine NK cells. It can be hypothesized that high serum levels of 
Gal-1 are associated with MS amelioration during pregnancy.
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Prediction and possible treatment of postpartum relapse: future perspectives
In the absence of good clinical predictors of postpartum relapse we are in need of biomarkers. 
We found that high serum levels of the chemokine IL-8 during the first trimester were 
associated with a high chance of postpartum relapse.9 Although the negative predictive 
value was high, the low positive predictive value will limit direct clinical use. Another 
study shows that low serum levels of soluble HLA-G during pregnancy in MS patients are 
associated with an increased risk of a postpartum relapse.82 A possible predictive value of 
serum levels of soluble HLA-G remains to be investigated. No other studies investigating 
biomarkers for predicting postpartum relapse have been published. Ideally, such a biomarker 
should be able to predict postpartum relapse before delivery, in order to allow for patients 
and physicians to anticipate. Candidate biomarkers are summed in table 1.
The implication of a reliable predictor of a postpartum relapse is that a possible 
prophylactic treatment could be initiated. Both intravenous immunoglobulins (IVIG) and 
intravenous methylprednisolone have been studied.83-87 No prospective double-blind 
placebo-controlled studies on the use of IVIG or corticosteroids after delivery have been 
performed, so no definite positive advice on standard treatment with IVIG or corticosteroids 
after delivery can be given yet. Recently a study started on treatment after delivery with 
estradiol and progestin aiming to reduce postpartum relapses.88 The results from this study 
will be available soon.
 
Table 1. Potential biomarkers for prediction of postpartum relapse
Evidence for potential use as biomarker?
Hormonal Leptin Studies have shown no evidence
Vitamine D No, but needs validation
Estrogen No studies performed
Cortisol No studies performed
Prolactin No studies performed
Cytokines/chemokines IL-4 No studies performed
IL-10 No studies performed
IL-8 Yes, but needs validation in larger cohort
IL-17 No studies performed
IFN-γ No studies performed
Other immunological Exosomes No studies performed
Micro RNA No studies performed
Soluble HLA-G Yes, but predictive value needs to be assessed
Galectin-1 No studies performed
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Another approach might be continuation of interferon-β, copaxone or natalizumab during 
pregnancy or an early (re)start after delivery. Although there is some data suggesting that 
use of interferon-β and copaxone during the first weeks of pregnancy might be safe89-96, there 
is insufficient safety data on continuing these disease modulating drugs (DMD) throughout 
the entire pregnancy. An early start immediately after delivery is not likely to influence the 
increased risk of a postpartum relapse, as all of these DMD have a run-in period of several 
weeks to months, exceeding the acute phase after delivery.
A first step forward would be to perform a double-blind placebo-controlled study on IVIG 
and/or corticosteroids after delivery.
ii. ToWardS an early and reliable diaGnoSiS of MS in Childhood
What did we learn from our studies on childhood onset in MS
In the following part the main findings and conclusions of our studies on childhood onset of 
MS described in chapter 3.1, 3.2 and 3.3 will be discussed.
Prognostic factors after a first demyelinating attack in children
We performed a retrospective nationwide study in all large neuro-pediatric centres in 
The Netherlands, described in chapter 3.1.97 We included the full spectrum of acquired 
demyelinating syndromes (ADS) of the central nervous system (monofocal attacks and 
polyfocal attacks, with and without encephalopathy). 44% of the children with a monofocal 
attack developed MS, whereas 21% of the children with a polyfocal attack developed MS. We 
found that both the Barkhof MRI-criteria and the KIDMUS MRI-criteria were able to predict 
a future diagnosis of MS after a first demyelinating event. However, in very young children, 
aged under ten, we found that the sensitivity of especially the KIDMUS criteria was very low 
(18%). CSF analysis showed that an increased IgG index and presence of oligoclonal banding 
both were able to predict MS. Strikingly, children with and without encephalopathy both 
displayed MRI abnormalities as seen in typical ADEM cases (large lesions and basal ganglia/
thalamic lesions). 
Prediction of early relapse after diagnosis of MS in children
When children are to be selected for treatment trials with disease modulating drugs, it 
would be very useful to predict which children are likely to have a relapse shortly after 
the diagnosis of MS, indicative for a high disease activity. In the study described in chapter 
3.2 we found that the children with MRI features consistent with three or four out of the 
four Barkhof criteria for dissemination in space were more likely to have a relapse soon 
after their second, MS defining, attack.98 We could not reproduce the predictive value of the 
childhood-onset MS potential index for early severity as was proposed before.99
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MRI criteria for discriminating ADEM and MS
Recently, two new sets of MRI criteria were developed with the aim to aid in a reliable 
diagnosis of MS. One set of MRI criteria was developed to discriminate between MS and 
other neurological diseases causing white matter lesions (systemic lupus erythematosus 
(SLE) and migraine).100 Another set of MRI criteria was developed to discriminate MS from 
ADEM.101 In chapter 3.3 we investigated the capacity of all known diagnostic MRI criteria 
for children to differentiate MS from acute disseminated encephalomyelitis (ADEM).102 We 
found that the new Callen criteria for discriminating MS from ADEM were superior to the 
other sets of criteria.
Future perspective on improving diagnosis of MS in childhood
Important controversies about defining ADS
To improve the difficult diagnostic process in children, the international pediatric MS study 
group (IPMSSG) suggested a set of diagnostic criteria.103 However, several questions remain 
concerning these definitions and diagnostic criteria for ADS. Multiphasic disseminated 
demyelinating disease can be MS, recurrent ADEM or multiphasic ADEM, or an ADEM attack 
followed by a non-ADEM attack. The rationale for these several entities is that not every 
multiphasic disseminated demyelinating disease is MS, although dissemination in time and 
space criteria for the diagnosis MS are fulfilled. ADEM followed by a second demyelinating 
relapse can be a self-limiting disease with only two or three attacks and not a chronic 
lifelong disease like MS. Whether this approach is correct, will become clear after long-
term prospective follow up during the next years. Until then caution is warranted before 
diagnosing MS in children. 
 Another problem arises with the definition of ADEM. Currently ADEM is defined as a 
polyfocal attack with encephalopathy and typical ADEM features on MRI.103 We showed 
that children with polyfocal attacks without encephalopathy can also show typical ADEM 
MRI features.97 This indicates that encephalopathy may not be obligatory for a diagnosis of 
ADEM, as was also suggested by others.104-105 Using the IPMSSG definitions, an ADEM type 
attack may not be taken into account when making a diagnosis of MS. Using a too strict 
definition for ADEM may falsely allow children with polyfocal attacks with ADEM-type MRI 
abnormalities, but without encephalopathy, to be grouped into the group eligible for future 
MS diagnosis. 
 When a first ADEM episode is followed by a second ADEM episode the diagnosis of 
multiphasic or recurrent ADEM can be made, based on the presence of respectively new 
or only old symptoms. Whether multiphasic ADEM and recurrent ADEM are two distinct 
entities is disputable. No rationale was provided for separating recurrent ADEM cases and 
multiphasic cases in the consensus statement by the IPMSSG. Recent studies show that only 
a minority of relapsing ADEM cases fulfil the criteria for recurrent ADEM.97,105-108 The number 
of recurrent ADEM cases, described in literature is small and currently it is unknown if 
outcome is different in multiphasic or recurrent ADEM.
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MRI diagnostic criteria in children
Multiple studies have shown that the Barkhof criteria, used in adult MS, are also valuable 
in childhood MS [109-110].109-110 The KIDMUS criteria have been shown to differentiate 
between monophasic and multiphasic ADS.110 We validated both the Barkhof criteria and 
KIDMUS criteria in children with ADS, and found a high specificity but mediocre sensitivity 
for both criteria. Especially the sensitivity of the KIDMUS criteria was low (18%) in the group 
younger than 10 years. The KIDMUS criteria are not the only MRI criteria for the diagnosis 
MS in a paediatric population. The Callen diagnostic MS criteria were shown to differentiate 
between MS and other diseases (migraine and SLE) at the time of the second attack.100 
Differentiating between migraine and MS will not likely be a true diagnostic dilemma. 
Exploring the capacity of these Callen diagnostic MS MRI criteria to differentiate between 
MS and other ADS in a full pediatric ADS spectrum cohort at time of the first attack would 
be more useful. 
 The Callen ADEM-MS criteria were found to differentiate between MS and ADEM cases in 
childhood.101 Unfortunately, only a selection of ADS cases was included in this study, namely 
children that eventually would develop MS and typical monophasic ADEM cases. No cases 
of multiphasic or recurrent ADEM were included. We were able to reproduce the findings 
from this study.102 Despite the fact that our definition of ADEM did not require the presence 
of encephalopathy, we still found similar results. This again stresses that encephalopathy 
may not be obligatory for the diagnosis ADEM.
 For the diagnosis of MS in adults the new 2010 revised McDonald diagnostic criteria 
have been proposed.111 For fulfilment of dissemination in space (DIS) criteria one or more T2 
lesion(s) are required in at least two of the following four areas of the CNS: (1) periventricular, 
(2) juxtacortical, (3) infratentorial and (4) spinal cord. When a subject has a brainstem or 
spinal cord syndrome, the symptomatic lesions are excluded from the criteria and do not 
contribute to lesion count. These DIS MRI criteria should be evaluated in a paediatric ADS 
cohort.
 The clinical relevance of dissemination in time (DIT) MRI criteria has not been studied 
systematically in children yet. Using MRI for DIT in children may result in an earlier 
diagnosis. The role of a second MRI may prove especially interesting in children with ADEM 
and ADEM-like disease, because new, clinically silent lesions are thought to be rare in ADEM 
and multiphasic ADEM and may be a sign the diagnosis of MS.112
International collaboration
MS in children is a rare disease. Therefore, international collaboration is crucial to ensure 
a large enough number of patients, critical for answering the many unresolved questions. 
Possible regional differences in incidence and clinical features worldwide also make that 
an international approach is essential. The IPMSSG is an example of such a worldwide 
collaboration. It forms a network of clinicians, basic scientists and representatives of MS 
societies, dedicated to improve healthcare and research in pediatric MS and other forms of 
ADS. 
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The first step forwards is the use of international accepted definitions for pediatric MS 
and other ADS by collaborative international multicentre studies. These definitions should 
address the controversies mentioned in the sections above. We also need standardized, long 
term, prospective follow-up data on disease course, including a standardized MRI follow-up 
protocol in the full spectrum of children with ADS.  
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Chapter 1, the introduction, summarizes current knowledge regarding two special and 
different situations in multiple sclerosis (MS): Childhood onset MS and MS during pregnancy.
Chapter 2 describes the clinical (chapter 2.1-2.3) and biological studies (chapter 2.4-2.6) on 
pregnancy and MS. In chapter 2.1 we studied the clinical course of multiple sclerosis before, 
during and after pregnancy. We found that the relapse rate increased in the first three 
months after delivery, yet normalized within one year after delivery. Health-related quality 
of life (QoL) was improved during pregnancy, most appreciated in the MOS 36 item short 
form health survey questionnaire (SF-36) domains vitality and general health. Nine months 
or more after delivery we found no adverse effects on MS disease activity at group level, 
measured by the expanded disability status scale (EDSS), multiple sclerosis impact scale 29 
(MSIS-29), and the Guy’s neurological disability scale (GNDS). Nine months or more after 
delivery QoL, measured by the SF-36, was not unfavorably altered when compared with 
QoL during pregnancy. This indicates that, although the number of relapses is increased in 
the short term after delivery, there are no adverse effects of pregnancy on disease course 
in the mid-long term after delivery. Until now the only known predictors of a postpartum 
relapse are: number of relapses in the year preceding pregnancy, number of relapses during 
pregnancy and duration of disease. We were not able to reproduce these findings. In chapter 
2.2 we describe data on breastfeeding and disease activity that does not support the recent 
claim that breastfeeding protects against postpartum relapse. In chapter 2.3 we found 
that high serum levels of the chemokine interleukin-8 (IL-8) during the first trimester were 
associated with postpartum relapse. The low positive predictive value will likely limit clinical 
use of IL-8 as a predictor of postpartum relapse. In chapter 2.4 we performed a genome 
wide approach on alterations of the transcriptome of monocytes of MS patients before and 
during the third trimester of pregnancy. We found that during pregnancy expression of 
the Fc receptor CD64 was increased. Our results therefore support the hypothesis that the 
innate arm of the immune system is more activated during pregnancy. In chapter 2.5 we 
investigated the numbers of circulating regulatory T cells (Treg) and T helper (Th)17 cells. 
Unexpectedly, we found that the numbers of circulating Treg were decreased, during the 
first and third trimester of pregnancy in both MS patients and healthy controls. We found 
no differences in the frequencies of circulating Th17 cells during pregnancy in MS patients 
and healthy controls. We concluded that our results did not support our hypothesis that 
peripheral blood Th17 and Treg cells are directly involved in MS disease course alteration 
during pregnancy. In chapter 2.6 we studied serum levels of leptin before, during and after 
pregnancy in MS patients and healthy controls. We observed a significant increase in serum 
levels of leptin in women with MS during the third trimester, compared to baseline and 
first trimester samples. Serum levels of leptin during pregnancy were not associated with a 
postpartum relapse. Therefore, serum levels of leptin during pregnancy cannot be used as a 
biomarker for postpartum relapse. We found that women with MS with the largest relative 
decrease in serum leptin levels after delivery more often had a postpartum relapse. 
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Chapter 3 describes the studies on childhood onset in MS. We performed a retrospective 
nationwide study in all large neuro-pediatric centers in The Netherlands, described in 
chapter 3.1. We included the full spectrum of acquired demyelinating syndromes (ADS) of 
the central nervous system. 44% of the children with a monofocal attack developed MS, 
whereas 21% of the children with a polyfocal attack developed MS. Both the Barkhof MRI-
criteria and the KIDMUS MRI-criteria were able to predict a future diagnosis of MS after a 
first demyelinating event. In the very young, aged under ten, we found that the sensitivity of 
especially the KIDMUS criteria was very low (18%). Cerebrospinal fluid (CSF) analysis showed 
that an increased IgG index and presence of oligoclonal banding both were able to predict 
MS. Strikingly, children with and without encephalopathy both display MRI abnormalities 
as seen in typical acute disseminated encephalomyelitis (ADEM) cases (large lesions and 
basal ganglia/thalamic lesions). In chapter 3.2 we found that children with MS, with MRI 
features consistent with three or four out of the four Barkhof criteria for dissemination in 
space, were more likely to have a relapse soon after their second, MS defining, attack. We 
could not reproduce the predictive value of the childhood-onset MS potential index for early 
severity. In chapter 3.3 we investigated the capacity of all known diagnostic MRI criteria for 
children to differentiate MS from acute disseminated encephalomyelitis (ADEM). We found 
that the Callen criteria for discriminating MS from ADEM had the best test properties.
In chapter 4, the discussion, the observations from the studies in chapter 2 and 3 are 
summarized and discussed in relation to current literature. Recommendations for further 
research are described.
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Hoofdstuk 1, de introductie, vat de huidige kennis samen over twee bijzondere en 
verschillende situaties bij multipele sclerose (MS): Debuut van MS op de kinderleeftijd en 
MS tijdens zwangerschap.
In hoofdstuk 2 worden de klinische (hoofdstuk 2.1-2.3) en biologische studies (hoofdstuk 
2.4-2.6) over zwangerschap en MS beschreven. hoofdstuk 2.1 gaat over het klinisch beloop 
van MS voor, tijdens en na de zwangerschap. Het aantal MS aanvallen nam toe gedurende 
de eerste drie maanden na de bevalling. Eén jaar na de bevalling normaliseerde het aantal 
aanvallen weer. Gezondheidgerelateerde kwaliteit van leven (KvL) was verbeterd tijdens de 
zwangerschap. Dit was het meest duidelijk zichtbaar bij de MOS 36 item short form health 
survey questionnaire (SF-36) domeinen vitaliteit en algehele gezondheid. Minimaal negen 
maanden na de bevalling vonden we geen nadelige effecten van zwangerschap op MS 
ziekteactiviteit, gemeten door de expanded disability status scale (EDSS), multiple sclerosis 
impact scale 29 (MSIS-29) en Guy’s neurological disability scale (GNDS). Minimaal negen 
maanden na de bevalling was ook KvL, gemeten door de SF-36, niet ten nadele veranderd, 
vergeleken met KvL tijdens de zwangerschap. Dit betekent dat er geen nadelige effecten 
zijn van zwangerschap op ziekteactiviteit op de middellange termijn, ondanks de verhoogde 
ziekteactiviteit direct na de bevalling. De enige bekende voorspellers van een aanval direct 
na de bevalling zijn: het aantal aanvallen in het jaar voorafgaand aan de zwangerschap, het 
aantal aanvallen tijdens de zwangerschap en de duur van ziekte. Wij hebben de voorspellende 
waarde van deze parameters niet kunnen bevestigen. Hoofdstuk 2.2 gaat over borstvoeding 
en ziekteactiviteit. Enige tijd geleden werd een artikel gepubliceerd dat melding maakte van 
de mogelijk beschermende rol van borstvoeding tegen een aanval direct na de bevalling. 
Wij hebben geen aanwijzing voor een beschermende rol van borstvoeding tegen een 
aanval direct na de bevalling gevonden. In hoofdstuk 2.3 vonden we dat een hoge waarde 
in serum van het chemokine interleukine-8 (IL-8) tijdens het eerste trimester geassocieerd 
was met een MS aanval direct na de bevalling. De lage positief voorspellende waarde zal 
waarschijnlijk het gebruik van IL-8 als voorspeller in de praktijk beperken. In hoofdstuk 2.4 
bespreken we een studie naar de veranderingen van het transcriptoom van monocyten van 
MS patiënten, voor en tijdens de zwangerschap. We vonden dat tijdens de zwangerschap de 
expressie van de Fc receptor CD64 verhoogd was. Deze resultaten ondersteunen daarmee 
de hypothese dat aangeboren immuniteit meer geactiveerd is tijdens de zwangerschap. 
Hoofdstuk 2.5 gaat over het percentage circulerende regulatoire T cellen (Treg) en T helper 
(Th)17 cellen. Tegen onze verwachting in vonden we dat het aantal circulerende Treg 
gedaald was tijdens het eerste en derde trimester van de zwangerschap bij MS patiënten en 
gezonde controles. We vonden geen verschillen in percentages van circulerende Th17 cellen 
tijdens en na de zwangerschap bij MS patiënten en gezonde controles. Wij concludeerden 
dat circulerende Treg en Th17 cellen niet direct betrokken zijn bij de verbetering van MS 
tijdens de zwangerschap. In hoofdstuk 2.6 beschrijven we een studie naar serumwaarden 
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van leptine voor, tijdens en na de zwangerschap bij MS. We observeerden dat leptine 
significant verhoogd was tijdens de zwangerschap bij MS patiënten, vergeleken met voor 
de zwangerschap en tijdens het eerste trimester van de zwangerschap. Leptine waarden in 
serum tijdens de zwangerschap waren niet geassocieerd met een aanval in de eerste drie 
maanden na de bevalling. Daarom kan leptine niet gebruikt worden om een aanval direct 
na de bevalling te voorspellen. Wel vonden we dat vrouwen met de grootste relatieve daling 
in serum waarden van leptine na de bevalling de grootste kans hadden op een aanval in de 
eerste drie maanden na de bevalling.
In hoofdstuk 3 worden de studies over debuut van MS op de kinderleeftijd besproken. 
Hoofdstuk 3.1 gaat over een retrospectieve studie, waarbij alle grote kinderneurologische 
centra in Nederland participeerden. Wij includeerden kinderen met aandoeningen binnen 
het volledige spectrum van verkregen auto-immuun demyeliniserende aandoeningen van 
het centrale zenuwstelsel. 44% van de kinderen met een monofocale aanval kreeg uiteindelijk 
de diagnose MS. Van de kinderen met een polyfocale aanval werd bij 21% uiteindelijk de 
diagnose MS gesteld. Wij vonden dat zowel de Barkhof MRI criteria en de KIDMUS MRI 
criteria in staat waren om een uiteindelijke diagnose MS te voorspellen ten tijde van de 
eerste aanval. Echter, bij kinderen jonger dan tien jaar was de sensitiviteit van met name de 
KIDMUS MRI criteria erg laag (18%). Analyse van de liquor cerebrospinalis toonde dat een 
verhoogde IgG index en de aanwezigheid van oligoklonale banden in liquor cerebrospinalis 
een toekomstige diagnose MS konden voorspellen. Opvallend was dat zowel kinderen met 
als zonder encephalopathie afwijkingen op de MRI hebben, die typisch zijn voor een acute 
gedissemineerde encephalomyelitis (ADEM) (grote afwijkingen en afwijkingen in de basale 
kernen en thalamus). In hoofdstuk 3.2 vonden we dat kinderen met MS, waarbij de MRI 
ten tijde van de eerste aanval aan minimaal drie van de vier Barkhof MRI criteria voor 
disseminatie in plaats voldeed, sneller een aanval krijgen na hun tweede aanval. We konden 
de voorspellende waarde van de childhood-onset MS potential index for early severity, 
ontworpen om snelle progressie van MS te voorspellen, niet aantonen. In hoofdstuk 3.3 
beschrijven we de capaciteit van alle bekende diagnostische MRI criteria bij kinderen om MS 
van ADEM te differentiëren. Wij vonden dat van alle vier onderzochte criteria sets de Callen 
criteria voor het onderscheid tussen ADEM en MS de beste test eigenschappen hadden.
In hoofdstuk 4, de discussie, worden alle bevindingen van de studies uit hoofdstuk 2 
en 3 samengevat en besproken in relatie tot de huidige literatuur. Vervolgens worden 
aanbevelingen voor toekomstig onderzoek gedaan.
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ADEM:  Acute disseminated encephalomyelitis
ADS:  Acquired demyelinating syndromes 
ANKRD22:  Ankyrin repeat domain 22
APC:   Antigen presenting cell
BBB:  Blood brain barrier 
BMI:  Body mass index 
CIS:  Clinically isolated syndrome 
CNS:  Central nervous system 
CRH:  Corticotrophin releasing hormone
CPT:  Cell preparation tubes
CSF:   Cerebrospinal fluid
DIS:  Dissemination in space 
DIT:  Dissemination in time 
DMD:  Disease-modifying drugs
EAE:  Experimental autoimmune/allergic encephalomyelitis
EDSS:  Expanded disability status scale
ELISA:  Enzyme-linked immunosorbent assay
FcgR1a:  Fc gamma receptor 1a 
FLAIR:   Fluid attenuated inversion recovery
FoxP3:  Forkhead box transcription factor p3
Gal-1:  Galectin 1 
GNDS:   Guy’s neurological disability scale
HLA:  Human leucocyte antigen
IDO:  Indoleamine-2,3 dioxygenase
IFN-γ:  Interferon γ 
IL:  Interleukin
IPMSSG:  International paediatric MS study group 
IQR:   Interquartile range
IVIG:  Intravenous immunoglobulins 
JAK2:  Janus kinase 2 
KIR:  Killer cell immunoglobulin-like receptor
MFI:  Mean fluorescence intensity 
MHC:  Major histocompatiblity complex 
MOG:  Myelin oligodendrocte glycoprotein 
MRI:  Magnetic resonance imaging 
mRNA:  Messenger RNA
MS:  Multiple sclerosis 
MSIS- 29:  Multiple sclerosis impact scale 29 
NK:  Natural killer
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OCB:  Oligoclonal bands 
PBMC:  Peripheral blood mononuclear cells
PP-MS:  Primary progressive multiple sclerosis
PCIS:  Polyfocal clinically isolated syndrome 
PTX3:  Pentraxin 3
QoL:  Quality of life
RA:  Rheumatoid arthritis
RR-MS:  Relapsing remitting multiple sclerosis
RT-PCR:  Real time polymerase chain reaction
SAM:  Statistical analysis of microarrays 
SD:  Standard deviation
SF36:  MOS 36 item short form health survey questionnaire
sHLA-G:  Soluble HLA-G 
SLE:  Systemic lupus erythematosus
SLR:  Soluble leptin receptor 
STAT1:  Signal transducer and activator of transcription 1
T-bet:  T box transcription factor
TGF- β:  Transforming growth factor β
Th:  Thelper
TNF- α:  Tumor necrosis factor alpha
Treg:  Regulatory T cells 
VEP:   Visual evoked potential 
VEGF:  Vascular endothelial growth factor 
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Rinze Frederik Neuteboom was born on the 24th of November 1976 in Apeldoorn, The 
Netherlands. He attended secondary school at the Stedelijk Gymnasium Apeldoorn, from 
which he graduated in 1995. He started medical school in 1995 at the Erasmus University 
of Rotterdam. During this period he worked at the Department of Neuro-Anatomy assisting 
classes of neuro-anatomy. In 2001 he graduated from medical school cum laude and started 
his residency in Neurology at the Department of Neurology at the Erasmus MC in Rotterdam 
(head: Prof. Dr. P.J. Koudstaal, later Prof. Dr. P.A.E. Sillevis-Smitt). He finished his Neurology 
training in 2010. From 2003 he combined his residency with the research underlying this 
thesis with Prof. Dr. R.Q. Hintzen and Prof. Dr. J.D. Laman. In 2009 he started a two year 
clinical fellowship in Pediatric Neurology under Prof. Dr. W.F.M. Arts, including a one year 
residency in Pediatrics under Dr. M. De Hoog. Since 2011 he has been working as a pediatric 
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Phd PorTfolio: SuMMary of Phd TraininG and TeaChinG
1. PhD training Year
Workload
(ECTS)
General and specific courses
Biemond courses 2002, 2003, 2004, 2005, 2006, 2007, 2008, 
2009, 2010, 2011
ESNI neuro-immunology course
2002
5.7
1.2
Seminars and workshops
Voorjaarsvergadering NVKN 2007,2008,2009,2010,2011 1.0
Presentations
MS research dagen (2 oral presentations)
ECTRIMS (oral presentation)
Voorjaarsvergadering NVKN (oral presentation)
Wetenschappelijke vergadering NVN (oral presentation)
EPNS (oral presentation)
ACTRIMS/ECTRIMS/LACTRIMS ( 2 poster presentations)
MS research dagen (oral presentation)
ECTRIMS (poster presentation)
MS research dagen (oral presentation)
ECTRIMS (poster presentation)
2006
2006
2007
2007
2007
2008
2008
2009
2011
2011
2.0
1.0
1.0
1.0
1.0
2.0
1.0
1.0
1.0
1.0
(Inter)national conferences
MS research dagen 2002, 2003, 2004, 2005, 2006, 2008, 2011
ECTRIMS 2006, 2009, 2011
EPNS
ACTRIMS/ECTRIMS/LACTRIMS
ISPNO
2007
2008
2011
4.0
2.7
1.0
1.0
1.0
2. Teaching
Nascholing regionale neurologen Zuid-West Nederland
Najaarsvergadering NVKN
Pediatric Neurology Training for residents in pediatrics
Training neuro-pediatric nurses 2010, 2011
MOLMED training 2005, 2008, 2011
2007
2009
2010
0.5
0.5
0.5
0.5
1.5
Total 33.1




